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Schizophrenia is a severe psychiatric disorder that is hypothesized to represent the 
most extreme manifestation of a continuum of impairment referred to as schizotypy. As 
such, many of the cognitive, clinical, behavioral, and neuroanatomical features of 
schizophrenia should be present and detectable in nonpsychotic individuals who share 
this vulnerability. Recent findings have led to a renewed interest in the role that the gene 
that codes for catechol-O-methyltransferase (COMT) plays in the development and 
expression of schizotypy and schizophrenia. Specifically, an amino-acid polymorphism 
(Val158Met) in the COMT gene has been associated with schizophrenia based on linkage 
and association studies, with schizotypy in nonpsychotic adults, and with performance on 
dopamine-mediated prefrontal functioning in healthy adults and in patients with 
schizophrenia. Since abnormal functioning in dopaminergic pathways is thought to be 
associated with schizophrenia, COMT activity may play a role in schizophrenia 
pathogenesis and expression. The COMT gene is housed at 22q11.2, which maps to the 
commonly deleted region in 22q11 Deletion Syndrome (22q11DS), a syndrome that is 
associated with a highly elevated risk for the development of psychosis.  
The present study investigated the relationship of COMT genotype with 
neuropsychological impairment and social functioning in a nonpsychotic sample of 
children with 22q11DS. As hypothesized, participants with the Val allele performed 
worse on some measures of prefrontal functioning than participants with the Met allele. 
   
Additionally, participants with the Val allele exhibited schizophrenic-like social and 
behavioral deficits. Finally, associations between social and cognitive functioning and a 
haplotype that has been linked to schizophrenia were examined in patients with 
22q11DS. 
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CHAPTER I 
INTRODUCTION 
 
 
The present study examined the relationships of schizophrenic-like 
neurocognitive and behavioral deficits with the catechol-O-methyltransferase (COMT) 
Val158Met polymorphism in children and adolescents with 22q11 Deletion Syndrome 
(22q11DS).  The Val allele has been associated with a variety of features including 
cognitive deficits, behavior problems in children, self-reported schizotypy, and elevated 
rates of psychiatric disorders in 22q11DS patients, as well as in normal children and 
adults.  Retrospective studies suggest that 22q11DS is strongly associated with the 
occurrence of psychotic disorders in adulthood, and is associated with specific cognitive 
deficits in prefrontally-mediated domains and with behavioral dysfunction.  Additionally, 
the present work examined the relationship of proposed vulnerability haplotypes with 
neurocognitive and symptom measures.  The present study integrates findings from the 
COMT, schizophrenia, 22q11DS, and schizotypy literatures to provide an integrated 
approach to the investigation of schizophrenic-like neurocognitive and behavioral 
impairment. 
Schizophrenia and Schizotypy 
Schizophrenia is a severe psychiatric disorder affecting approximately 1% of the 
general population (Gottesman, 1991; Tsuang & Faraone, 1998).  Evidence from twin, 
adoption, and family studies indicates a substantial genetic contribution to this disorder.  
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However, transmission is complex, and the number of genes responsible, location 
of these genes, and their modes of transmission are not well understood.  Schizophrenia 
appears to be best conceptualized as a neurodevelopmental disorder (e.g. Andreasen, 
1999; Weinberger, 1987) culminating in abnormal brain organization that constitutes 
vulnerability to schizophrenia.  A neurodevelopmental model of schizophrenia implies a 
neurobiological basis for pathogenesis, and such a conceptualization has led to the search 
for genes and neurological pathways of impact based on theoretical models and 
correlational evidence.   
Schizotypy is defined as the personality organization that conveys risk for the 
development of schizophrenia, and is believed to reflect underlying neurodevelopmental 
disorganization (Meehl, 1962/1990; Tsuang, Stone, & Faraone, 2000).  Schizotypy is 
expressed on a dynamic continuum of adjustment ranging from well-compensated to 
psychotic.  This continuum of adjustment includes milder variants of the disorder such as 
schizotypal personality disorder, with severity contingent on the interaction of 
biopsychosocial factors (Gooding & Iacono, 1995).  That is, vulnerability to psychosis 
and spectrum disorders, as well as nonclinical personality organizations that reflect mild 
variants of this dysmaturation, has a basis in neuromaldevelopment that may be set in 
motion by a number of factors.  These factors may include combinations of genetic, 
biological, and environmental variables that disrupt neural development, organization, 
and functioning beginning in utero.  These factors interact in complex ways with 
environmental and developmental factors resulting in both vulnerability to schizophrenia 
and movement along the continuum of schizotypy.  For instance, Caspi et al. (2005) 
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found that cannabis use prior to age 15 in participants with a particular gene variant (the 
Val version of the Val158Met polymorphism) was associated with schizophreniform 
disorders in early adulthood based on prospective investigation.  However, cannabis use 
later in development evidenced no relationship to this genotype in terms of development 
of schizophreniform disorders.  These findings highlight the complex interplay of 
genetic, environmental, and developmental factors in the development of psychosis.   
It is assumed that the majority of schizotypes will never decompensate; however, 
since compensated schizotypes are hypothesized to share a common neurodevelopmental 
pathway with schizophrenia patients, it is expected that they will exhibit subclinical and 
transient clinical forms of the biological, cognitive, emotional, and behavioral features of 
schizophrenia.  Thus, markers of vulnerability and associated features should be 
detectable in patients with schizophrenia-spectrum disorders and in nonpsychotic people 
identified as schizotypic, including first degree relatives, patients with identified genetic 
risk markers, and people identified by psychometric measures.  Additionally, 
nondisordered schizotypes who exhibit these features should be more likely to develop 
schizophrenia-spectrum disorders.   
Indeed, studies show that nonpsychotic individuals psychometrically identified as 
schizotypic, and people believed to share a genetic liability to schizophrenia including 
first degree relatives of schizophrenia patients and patients with 22q11DS, have higher 
rates of psychotic disorders and schizophrenia-spectrum illnesses at follow-up 
assessments than do control participants (Bassett & Chow, 1999; Chapman, Chapman, 
Kwapil, Eckblad, & Zinser, 1994; Erlenmeyer-Kimling et al., 2000; Kendler, Neale, & 
3 
 
Walsh, 1995; Kwapil, 1998; Murphy, Jones, & Owen, 1999; Pulver et al., 1994).  
Longitudinal research suggests that a substantial percentage (20-40%) of youth with 
schizotypal symptoms go on to develop an Axis I schizophrenia spectrum disorder 
(Miller et al., 2002), and nonpsychotic monozygotic co-twins of schizophrenia patients 
appear to transmit this vulnerability to their offspring at the same rate as their 
schizophrenic siblings (Gottesman & Bertelsen, 1989).   
Additionally, nonpsychotic schizotypes exhibit many of the cognitive, behavioral, 
and neurobiological features identified in schizophrenia patients, including deficits in 
prefrontal cognitive functioning, neurological soft signs, motor abnormalities, affective 
flattening, and behavioral and social skills deficits (Bearden et al., 2004; Bearden et al., 
2005; Diforio, Walker, & Kestler, 2000; Erlenmeyer-Kimling et al., 2000; Gerdes et al., 
1999; Lenzenweger & Dworkin, 1998; Lewandowski, Shashi, Berry, & Kwapil, 2007; 
Murphy et al., 1999; Swillen, Vogels, Devriendt, & Fryns, 2000; Walker, Kestler, 
Bollini, & Hochman, 2004; Weinstein, Diforio, Schiffman, Walker, & Bonsall, 1999; 
Weinberger & Berman, 1988).  The presence of features associated with schizophrenia in 
nonpsychotic individuals identified as schizotypic, together with increased risk for 
development of schizophrenia and spectrum disorders, supports a continuum of 
expression of the neurodevelopmental vulnerability to psychosis. 
While genetic factors are believed to play an important role in the pathogenesis of 
schizophrenia, it is unlikely that a single gene or genetic variant is the sole cause of the 
complex constellation of cognitive, behavioral, experiential, neurochemical, and 
neuroanatomical traits (among others) that make up the disorder.  Rather, genetic variants 
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may map more closely to specific features or traits associated with schizophrenia.  These 
are likely to be features that are present and detectable prior to onset of frank psychosis 
and in at-risk individuals who may never decompensate.  
Cognitive Functioning as a Marker of Schizotypy  
It has been hypothesized that prefrontal pathophysiology is central to 
schizophrenia and is associated with dysregulation in dopaminergic transmission 
(Bertolino et al., 2000).  Cognitive deficits in sustained attention, executive functioning, 
and working memory – functions believed to be mediated by prefrontal cortex – have 
been widely reported in schizophrenia patients (Aloia, Gourovitch, Weinberger, & 
Goldberg, 1996; Cohen, Braver, & O’Reilly, 1996; Gold & Harvey, 1993; Goldberg, 
Weinberger, Berman, Pliskin, & Podd, 1987; Goldman-Rakic, 1994; Green, Kern, Braff, 
& Mintz, 2000; Heinrichs & Zakzanis, 1998; Kuperberg & Heckers, 2002; Lenzenweger 
& Dworkin, 1998; Park & Holzman, 1992; Riley et al., 2000).  Additionally, similar 
patterns of neurocognitive impairment have been reported in individuals identified as 
schizotypic based on diagnosis of spectrum disorders (e.g. schizotypal personality 
disorder), first degree relative status, and psychometric identification (Barrantes-Vidal, 
Caparros, & Obiols, 1999; Bergman et al., 1998; Cornblatt, Risch, Faris, Friedman, & 
Erlenmeyer-Kimling, 1988; Lyons et al., 1995; Minzenberg et al., 2006; Saykin et al., 
1991; Voglmaier, Seidman, Salisbury, & McCarley, 1997).  In children of schizophrenia 
patients, such deficits have been found to predict which offspring would go on to develop 
schizophrenia and spectrum disorders (Erlenmeyer-Kimling et al., 2000).  The presence 
of such cognitive impairment in individuals who have been identified as schizotypic 
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demonstrates the existence of this cognitive profile absent the effects of medication, 
hospitalization, or the catastrophic nature of the disorder itself, thus lending support for 
cognitive dysfunction as a marker of neurodevelopmental liability.   
Social and Behavioral Functioning as Markers of Schizotypy 
Social impairment is a central feature of schizophrenia and, consistent with the 
continuum hypothesis of schizotypy, social dysfunction is detectable in patients with 
spectrum disorders and people identified as at-risk based on genetic liability or 
psychometric identification.  Social impairment is widely described as a hallmark of the 
prodromal, active, and residual phases of schizophrenia, and it is a central feature of 
schizophrenia-spectrum conditions such as schizoid and schizotypal personality disorders 
(American Psychiatric Association, 2001). The social impairment associated with 
schizophrenia and spectrum disorders includes isolation, disinterest in social contact, and 
social anxiety. Both Kraepelin (1919) and Bleuler (1950) emphasized asociality as a 
feature of patients with schizophrenia, even during the premorbid phase. Social 
impairment, especially asociality, also played a central role in Rado’s (1956) model of 
the development of schizophrenia, which greatly influenced Meehl’s (1962, 1990) theory 
of schizotypy.  More recently, social impairment has been described as a feature of 
schizotaxia, a condition that is proposed to convey the liability for schizophrenia (Tsuang 
et al, 2000).  Likewise, social anxiety is part of the diagnostic criteria of schizotypal 
personality disorder, although recent formulations have limited this to paranoid 
expectations of mistreatment (American Psychiatric Association, 2001).  
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Social impairment has been found to be present in all clinical stages of 
schizophrenia and serves as an indicator of risk for developing the disorder in vulnerable 
individuals.  Empirical studies indicate that impairments in social functioning prior to 
decompensation predict later development of schizophrenia (Cannon et al., 2001; 
Davidson et al., 1999; Malmberg, Lewis, David, & Allebeck, 1998).  Poor social 
adjustment prior to first hospitalization was also associated with more days in the hospital 
for males who developed schizophrenia, but not for patients who developed mood 
disorders (Rabinowitz et al., 2005).  Additionally, Johnstone, Ebmeier, Miller, Owens, 
and Lawrie (2005) reported that high-risk participants who developed schizophrenia 
during a 2½-year longitudinal assessment had more social impairment than their 
counterparts who remained compensated. 
Family studies point to social impairment as a possible manifestation of the 
susceptibility for schizophrenia. Poor social adjustment has been reported in 
nonpsychotic people identified as schizotypic based on first-degree relative status. The 
Jerusalem Infant Development Study reported that adolescents with a schizophrenic 
parent demonstrated poorer peer engagement and more social problems than a control 
group (Hans, Auerbach, Asarnow, Styr, & Marcus, 2000). Additionally, the Edinburgh 
High-Risk Study found elevated rates of childhood social isolation in young adults 
identified as at-risk based on family history of schizophrenia (Hodges, Byrne, Grant, & 
Johnstone, 1999).  Thus, social dysfunction appears to be a promising marker of risk for 
the development of schizophrenia, and may be indicative of underlying pathophysiology 
associated with vulnerability to psychosis.  As such, it would be expected that social 
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dysfunction would be associated with genetic markers of vulnerability, even prior to 
decompensation.   
Catechol-O-Methyltransferase and Schizophrenia 
Several converging lines of evidence have led to a renewed interest in the role that 
the gene that codes for COMT plays in the development and expression of schizophrenia.  
These include the neurochemical functioning of COMT (Axelrod & Tomchick, 1958), its 
location, which maps to the commonly deleted region in 22q11DS (Grossman, Emanuel, 
& Budarf,  1992), and findings that a single nucleotide polymorphism (SNP) within the 
COMT gene may be associated with schizophrenic-like neurocognitive and behavioral 
symptoms as well as an increased risk for the development of schizophrenia and 
spectrum disorders (Avromopoulos et al., 2002;  Bearden et al., 2005; Bearden et al., 
2004; Egan et al., 2001; Glatt, Faraone, & Tsuang, 2003; Malhotra et al., 2002).   
COMT is an enzyme that catalyses the O-methylation of catecholamine 
neurotransmitters such as dopamine, adrenaline, and noradrenalin (Axelrod & Tomchick, 
1958; Karoum, Chrapusta, & Egan, 1994).  That is, COMT facilitates the degradation of 
active dopamine and other catecholamines in the synapse, and is believed to be the major 
enzyme responsible for this function in prefrontal cortex (Karoum et al., 1994).  A 
functional polymorphism with two common allelic variants (valine and methionine) 
affects the activity level of COMT, resulting in lower or higher levels of available 
catecholamines, respectively.  The presence of the amino acid valine (Val) heightens 
activation of COMT, resulting in increased catecholamine breakdown and less available 
neurotransmitter.  Conversely, the presence of the amino acid methionine (Met) is 
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associated with lower COMT activity, decreased catecholamine breakdown, and 
increased levels of available neurotransmitter.  Functionally, homozygosity for the low-
activity Met allele results in a three- to four-fold reduction of COMT activity compared 
with Val homozygotes (Graf et al., 2001; Lachman et al., 1996), leading to reduced 
degradation of synaptic catecholamines.  The alleles appear to be codominant, with 
heterozygotes’ enzyme activity midway between individuals who are Val/Val and 
Met/Met homozygous (Weinshilboum, Otterness, & Szumlanski, 1999).   
COMT, Dopamine, and Schizophrenia. COMT activity has an important impact 
on prefrontal dopamine levels, as transporter mechanisms that are present in other brain 
regions exhibit reduced expression in prefrontal cortex, or are not expressed at all 
(Sesack, Hawrylak, Matus, Guido, & Levey, 1998).  Dopamine has been associated with 
performance on tasks which recruit prefrontal cortical regions in animal models and in 
clinical and nonclinical human populations (Fournet, Moreaud, Roulin, Naegele, & 
Pellat, 2000; Medalia, Gold, & Merriam, 1988; Murphy, Arnsten, Jentsch, & Roth, 
1996).  Thus, COMT activity appears to affect prefrontal cognitive functioning via its 
effect on dopamine levels in the prefrontal cortex.  Furthermore, since this region does 
not have active dopamine transport mechanisms, synaptic dopamine availability plays an 
especially important role in functions subserved by dopamine in prefrontal cortex.  
Indeed, COMT inhibition, which increases the availability of dopamine in the prefrontal 
cortex, has been associated with improved set-shifting in rats, and COMT genotype has 
been shown to predict cognitive performance on executive functioning and working 
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memory tasks – believed to be mediated by the prefrontal cortex – in humans (Egan et al., 
2001; Malhotra et al., 2002; Bruder et al., 2005).   
Early formulations of the role of dopamine in schizophrenia implicated 
hyperdopaminergic functioning in subcortical regions with the production of positive 
symptoms (e.g. Abi-Dargham, 2004; Carlsson, 2006 for reviews).  Numerous studies 
supported a hyperdopaminergic model of schizophrenia; however, these findings did not 
address issues of negative symptoms, which in earlier formulations of schizophrenia were 
believed to represent the core syndrome (Bleuler, 1950; Kraepelin, 1919).  More recently, 
reductions in dopamine functioning in prefrontal cortex have been found to be associated 
with negative symptoms and cognitive impairment in schizophrenia.  Thus, some 
disconnect appears to exist between dopamine levels and symptoms in schizophrenia, 
with high levels in limbic regions implicated in positive symptoms and low levels in 
prefrontal cortex implicated in cognitive dysfunction and negative symptoms.   
A “reformulated” hypothesis of the role of dopamine in schizophrenia posits that 
hyperdopaminergic functioning in subcortical structures is associated with positive 
symptoms such as hallucinations and delusions, whereas hypodopaminergic functioning 
in prefrontal cortical regions is associated with specific cognitive deficits seen in 
schizophrenia, as well as negative symptoms such as avolition and anhedonia (Abi-
Dargham, 2004; Carlsson, 2006).  These relationships are believed to be interdependent, 
as compromised cortical-subcortical structure and connectivity may play a role in 
dysregulation of dopamine and dopaminergic transmission.  Swerdlow et al. (1995) 
showed that cell damage in frontal and temporal cortex increases sensitivity to effects of 
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dopamine receptor activation as demonstrated by disruption in sensorimotor gating of 
startle response in a rat model of schizophrenia.  Additionally, Flagstad et al. (2004) 
found that late gestational disruption of neurodevelopment in rats led to behavioral 
changes that resemble both positive and negative schizophrenia symptoms and may be 
related to dysregulation of dopamine and structural brain changes including reductions in 
cortical and subcortical structures, dysregulation of subcortical dopamine 
neurotransmission, hyper-responsiveness to stress and amphetamine, and less social 
interaction.  In a study of non-human primates, increasing levels of monoaminergic 
transmission in prefrontal cortex led to a gradual and significant decrease in dopamine 
levels in caudate nucleus (Kolachana, Saunders, & Weinberger, 1995).   
In humans, Bertolino et al. (2000) demonstrated that N-acetylaspartate (NAA) 
levels in dorsolateral prefrontal cortex predicted subcortical dopamine function in 
schizophrenic patients.  Furthermore, NAA measures in other cortical regions did not 
correlate with subcortical dopamine.  Decreased NAA concentrations have been found in 
prefrontal regions in patients with schizophrenia (see Abbott & Bustillo, 2006 for 
review), and reductions of NAA in the prefrontal cortex in patients has been associated 
with negative symptoms based on the Positive and Negative Symptom Scales (Kay, 
Fiszbein, & Opler, 1987) and with poorer cognitive functioning on the Wisconsin Card 
Sorting Test (WCST; Heaton, Chelune, Talley, Kay, & Curtiss, 1993), a task believed to 
tap prefrontal executive functioning.  Thus, pathophysiology of the prefrontal cortex may 
be directly related to functional abnormalities in subcortical dopaminergic transmission, 
11 
 
and may be associated with many of the features commonly seen in schizophrenia, 
including both positive and negative symptoms.   
COMT and cognitive functioning.  Abnormal functioning in dopaminergic 
pathways is thought to be associated with schizophrenia, suggesting that COMT activity 
may play a role in schizophrenia pathogenesis and expression.  Studies of nonhuman 
primates indicate that higher-level cognitive abilities depend critically on the 
dopaminergic projections to dorsolateral prefrontal cortex (Diamond, 1996).  
Functionally, COMT has been found to predict performance on executive functioning and 
working memory tasks.  A number of investigations have reported that the Val allele is 
related to poorer performance on such tasks in healthy control participants (Bilder et al., 
2002; Bruder et al., 2005; Malhotra et al., 2002).  Egan et al. (2001) reported that the Val 
allele is associated with poorer performance on the WCST, a test of executive processing 
believed to tap prefrontal cortical functioning (Chelune & Baer, 1986).  Additionally, 
Bruder et al. (2005) found that COMT genotypes were associated with performance 
differences on specific aspects of working memory tasks, but not others.  They reported 
that people with the Val/Val genotype performed worse than people with the Met/Met 
genotype on higher-order cognitive functions such as mental manipulation as measured 
by the WCST and the Letter-Number Sequencing Task, but that COMT genotype was not 
associated with more basic storage and maintenance functions as measured by the Spatial 
Delayed Response Task (Stratta et al., 1999), Word Serial Position Test (Wexler, 
Stevens, Bowers, Sernyak, & Goldman Rakic1998), and N-back (1- and 2-back) (Braver 
et al., 1997).   
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The relationship between Val158Met genotype and prefrontal functioning has been 
shown in patients with schizophrenia, as well.  In patients with schizophrenia, the Val 
allele has been associated with poorer performance on prefrontally-mediated 
neurocognitive tasks including executive functioning, processing speed, and attention 
compared with patients with Met/Met genotypes (Bilder et al., 2002; Goldberg et al., 
2003; Han et al., 2006; Weinberger et al., 2001; Woodward, Jayathilake & Meltzer, 
2007).  Additionally, schizophrenia patients with at least one Val allele exhibited P-300 
amplitudes and electrophysiological markers of prefrontal dysfunction, as well as poor 
performance on the Stroop (Ehlis, Reif, Herrman, Lesch, & Fallgatter, 2007), and 
neuromotor deficits (Galderisi et al., 2005).  The Val allele has been associated with 
cognitive deterioration in schizophrenia patients in a linear fashion, such that more Val 
alleles were associated with greater cognitive decline (Mata et al., 2006).  Similar 
findings have been reported in patients with schizotypal personality disorder, with the 
Val allele associated with poorer performance on the WCST and the Paced Auditory 
Serial Addition Test (Gronwall, 1977), a test of sustained attention (Minzenberg et al., 
2006). 
 The Val allele has also been associated with poor prefrontal cognitive functioning 
in people identified as at-risk for the development of schizophrenia.  Goldberg et al. 
(2003) found the same deficits in Val/Val unaffected siblings of schizophrenia patients as 
in the patients themselves, with Val homozygous siblings performing worse than Met 
homozygous siblings on a test of executive functioning.  Additionally, COMT was 
associated with performance on the WCST in patients with schizophrenia and their 
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unaffected siblings in a dose-dependent fashion, such that increasing Val load was 
associated with increasing deficits in perseverative errors (Egan et al., 2001).   
Recent evidence suggests that the effect of antipsychotic medication on prefrontal 
functioning is moderated by genotype.  Not only were executive functions and working 
memory better in schizophrenia patients with the Met allele, but treatment with 
antipsychotic medications improved cognitive performance in these domains in patients 
with the Met allele significantly more than in patients with the Val allele (Weickert et al., 
2004; Woodward et al., 2007).  These findings suggest that the Val158Met polymorphism 
is associated with differential prefrontal cognitive performance, and changes in cognitive 
functioning associated with pharmacological treatment may be mediated by COMT 
genotype. 
 It should be noted that not all reports confirm the association between the Val 
allele and cognitive deficits in patients with schizophrenia or in patients identified as 
schizotypic.  For instance, in a sample of Chinese patients with schizophrenia, the COMT 
Val158Met polymorphism was not significantly associated with global cognitive function, 
or with symptoms or prognosis (Tsai, Hong, Liao, Lai, & Liou, 2004), and Stefanis et al. 
(2004) failed to detect differences in cognitive functioning by genotype in nonpsychotic 
males psychometrically identified as schizotypic.  However, the relationship of COMT 
with schizophrenia, the role of COMT in cognitive functioning via dopaminergic activity, 
and a rich literature of specific cognitive deficits in prefrontally-mediated tasks in 
schizophrenic patients and people identified as vulnerable provides a possible 
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mechanistic rationale for the examination of the role of COMT in the pathogenesis of 
schizophrenia.  
Neuroimaging.  Given the relationships among COMT, dopaminergic 
functioning, neurocognitive performance, and schizophrenia, neuroimaging studies would 
be expected to demonstrate functional and/or structural differences between people based 
on genotype.  The COMT Val allele has been associated with reduced gray matter density 
in anterior cingulate cortex and right middle temporal gyrus compared to people with the 
Met genotype (McIntosh et al., 2007; Ohnishi et al., 2006).  Schizophrenic patients 
homozygous for the Val allele also showed a significant reduction of volumes in the 
bilateral Anterior Cingulate Cortex, as well as left amygdala-uncus, right middle 
temporal gyrus and left thalamus compared to patients with the Met allele (Ohnishi et al., 
2006).  Functionally, Met allele load had been shown to predict a more efficient 
physiological response in prefrontal cortex, while the Val allele has been associated with 
greater engagement of the prefrontal cortex when controlling for output (Bertolino et al., 
2006; Egan et al., 2001).  This indicates that the Val allele is associated with less efficient 
neurological processing on tasks of prefrontal functioning than the Met allele, even when 
task performance does not differ, suggesting that brain functioning in prefrontal cortex is 
compromised. 
COMT association and linkage.  Association studies have identified a number of 
schizophrenia susceptibility loci, among including genes in the chromosome 22q11 
region such as COMT (Berrettini, 2000; McGuffin, Tanden & Corsico, 2003; Owen, 
Williams, & O’Donovan, 2004).  Wonodi, Stine, Mitchell, Buchanan, & Thaker (2003) 
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found a significant association between Val allele frequency in schizophrenic patients 
compared to control participants, consistent with findings by Kremer et al. (2003).  
Family linkage studies have reported preferential transmission of the Val allele from 
parents to offspring with psychosis, and this result reached statistical significance when 
combined with another family linkage study (Glatt, Faraone, & Tsuang, 2003; Kunugi et 
al., 1997).  McIntosh et al. (2007) found that the Val allele increased risk for 
schizophrenia in biological relatives in a dose-dependent fashion, such that increasing 
Val allele load was associated with increasing risk for the development of the disorder.  
Additionally, the COMT Val allele was associated with schizophrenia in a large sample 
of Ashkenazi Jews, and the association was even stronger when a COMT haplotype, 
which included the Val allele, was examined (Shifman et al., 2002).  These findings 
support an association between COMT and schizophrenia; however, the nature of the 
association is unclear.  COMT may confer risk directly, may exhibit combined effects on 
outcome with additional polymorphisms within the COMT gene, or may be in linkage 
disequilibrium with a different susceptibility gene (Li et al., 1996; Shifman et al., 2002).  
It should be noted, however, that several studies found no association between COMT 
Val158Met genotype and schizophrenia (Bassett et al., 2007; Fan et al., 2005; Williams et 
al., 2005).   
Haplotype analysis.  Within the COMT gene, Val158Met is just one of a number of 
polymorphic alleles.  Several other candidate alleles have been examined including 
rs165599, rs737865, and the P2 promoter region [-278A/G; rs2097603], one or more of 
which has been associated with risk for schizophrenia in multiple reports (Chen, Wang, 
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O’Neill, Walsh, & Kendler, 2004; Li et al., 2000; Sanders et al., 2005; Shifman et al., 
2002).  Additionally, haplotype analyses have produced promising results by examining 
the association of multiple markers in the COMT gene with psychopathology.  Shifman 
et al. (2002) found that a three-marker COMT haplotype was significantly associated 
with schizophrenia in a large sample of Ashkenazi Jews.  This haplotype included 
Val158Met, as well as markers rs737865 and rs165599, with the G allele associated with 
risk in all three markers (this included the Val allele for COMT).  While the Val allele 
itself was significantly associated with schizophrenia, results indicated that the haplotype 
improved prediction significantly over any of the alleles alone.  A large case-control 
study examined the relationship of the above haplotype, including rs737865, Val158Met, 
and rs165599, in patients with psychosis (both mood and non-mood) and mood disorders 
(Funke et al., 2005).  Cases were patients with schizophrenia, schizoaffective disorder, 
bipolar disorder, major depressive disorder, psychotic disorder NOS, or depressive 
disorder NOS.  The findings indicated that Val158Met and rs165599 were associated with 
a broad “all affected” group, and that the “opposite” (A-A-A) haplotype (and G in the P2 
promotor regions [-278A/G; rs2097603]) was significantly underrepresented in the “all 
affected” group, suggesting that this haplotype may offer some protective benefit.   
Haplotype research appears promising; however, the Val158Met polymorphism 
continues to be of interest in and of itself, as the functional implications of variation at 
this locus in terms of neurochemistry are well-described.  Such an understanding of the 
functional results of variation at other COMT loci associated with schizophrenia has not 
yet been achieved. 
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Symptom and behavioral characteristics associated with COMT.  The relationship 
of COMT with other symptoms of psychosis has been less well studied in patients with 
schizophrenia; however, a recent report indicated that first-episode schizophrenia patients 
homozygous for the Val allele exhibited more inappropriate affect than patients with the 
Met/Met or Val/Met genotypes, while Met/Met and Val/Met patients had higher 
aggression scores (Han et al., 2006).  In contrast, Tsai et al. (2004) did not find 
differences in symptomatology based on genotype in patients with chronic schizophrenia, 
although their measures were more general assessments of mental status and social and 
occupational functioning.  Furthermore, the consequences of chronic schizophrenia may 
offset such differences.  These findings suggest that COMT may be associated with 
specific aspects of functioning and symptomatology rather than general level of 
functioning.   
Recent investigations have found higher rates of self-reported schizotypy in 
nonpsychotic males who were Val/Val homozygous than in Val/Met heterozygotes or 
Met/Met homozygotes, especially on negative and disorganized dimensions 
(Avramopoulos et al., 2002; Stefanis et al. 2004).  Similar findings were reported in a 
sample of control participants and unaffected siblings of schizophrenic and bipolar 
patients, with the Val allele associated with self-reported schizotypy (Schurhoff et al., 
2007).  Such behavioral difficulties have been associated with poor premorbid adjustment 
in people who develop schizophrenia based on retrospective reports and prospective 
follow-up (Bearden et al., 2000; Cannon et al., 1997; Jones, Rodgers, Murray, & Marmot, 
1994).  Thus, recent findings suggest that the COMT Val158Met polymorphism plays a 
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role in complex, dopamine-mediated prefrontal functioning, and that the Val allele is 
associated with schizophrenia-like neurocognitive deficits.  Additionally, COMT 
genotype may play a role in behavioral and symptom indicators of vulnerability to 
schizophrenia. 
COMT and other psychopathology. COMT has been associated with other 
psychopathology, as well, although findings tend to be mixed.  Driven by the functional 
implications of the Val158Met polymorphism’s effects on prefrontal catecholamine 
activity, disorders that have been hypothesized to involve dysregulation of these 
processes have been investigated, including Attention Deficit/Hyperactivity Disorder 
(AD/HD) and conduct disorder, which involve deficits in executive functioning and 
behavioral inhibition.  While some reports indicate that AD/HD, conduct disorder, and 
antisocial behavior are associated with the Val allele (Tharpar et al., 2005), many others 
have failed to find an association between genotype and these disorders (Cheuk & Wong, 
2006).   
Smolka et al. (2005) noted that the distribution of the Val allele in the general 
population, which is near 50% (Palmatier, Kang, & Kidd, 1999), is surprising given its 
seemingly deleterious effect on prefrontal functioning.  It has been suggested that the Met 
allele may be associated with risk factors as well, perhaps for anxiety and mood 
pathology (Enoch, Xu, Ferro, Harris, & Goldman, 2003).  Indeed, the Met allele has been 
associated with panic disorder (Woo et al., 2004), major depression (Ohara, Nagai, 
Suzuki, & Ohara, 1998b), obsessive-compulsive disorder (Karayiorgou et al., 1999), and 
bipolar disorder (Papolos, Veit, Faedda, Saito, & Lachman, 1998), and with ratings of 
19 
 
anxiety and negative affect (Enoch et al., 2003).  Gothelf et al. (2006) found an 
association with Met and AD/HD and OCD in patients with 22q11DS.  Additionally, 
Smolka et al. (2005) found that the number of Met alleles was associated with limbic and 
prefrontal brain response to negative but not positive visual stimuli.  It should be noted 
that they did not find any differences in depression or anxiety based on genotype, 
suggesting that genotype may be associated with patterns of neural activation in response 
to negative affective stimuli, but not with affective traits in normal subjects.  Again, 
however, a number of other reports have failed to find associations between genotype and 
mood disorders, obsessive-compulsive disorder, and anxiety and phobic disorders 
(Azzam & Mathews, 2003; Cusin et al., 2002; Lachman, Kelsoe, Moreno, Katz, & 
Papolos, 1997; Ohara, Nagai, Suzuki & Ohara, 1998a; Samochowiec et al., 2004), and 
Domschke et al. (2004) actually found an association between panic disorder and the Val 
allele in women. 
22q11 Deletion Syndrome 
As noted above, the COMT gene maps to the commonly deleted region in 
22q11DS, meaning that this genetic syndrome provides a unique vehicle for studying the 
effects of COMT and vulnerability for schizophrenia.  22q11DS is the most common 
microdeletion syndrome known in humans, affecting approximately 1 in every 2,000 to 
4,000 live births (Shprintzen, 2000).  22q11DS subsumes several conditions including 
DiGeorge Syndrome and Velo-Cardio-Facial Syndrome (VCFS), and is the result of a 
hemizygous deletion at band 11.2 on the long arm of chromosome 22 (Shprintzen, 2000).  
The syndrome has been widely linked to a variety of medical, cognitive, and 
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psychosocial deficits (Bassett & Chow, 1999; Bearden et al., 2004; Bearden et al., 2005; 
Gerdes et al., 1999; Murphy et al., 1999; Swillen et al., 2000).  Major congenital deficits 
include cardiac abnormalities, velopharyngeal insufficiency with or without a cleft palate, 
characteristic facial dysmorphology, hypoparathyroidism, and suppressed immune 
functioning (Shprintzen, 2000). While the deleted area can be variable and can involve 
deletions as large as 3Mb, the COMT gene is located in the 1.5 Mb “commonly-deleted” 
region in 22q11DS, meaning that all patients with 22q11DS have COMT 
haploinsufficiency.  
22q11 deletion syndrome and schizophrenia.  Retrospective findings have linked 
22q11DS with a markedly elevated rate of psychotic disorders such as schizophrenia and 
bipolar disorder (e.g., Bassett & Chow, 1999; Bassett et al., 1998; Gothelf et al., 1997; 
Papalos et al., 1996; Yan et al., 1998).  Murphy et al. (1999) reported that 24% of their 
sample of adult patients with VCFS was diagnosed with schizophrenia, and Pulver et al. 
(1994) reported that 31% of their sample of individuals with 22q11DS met criteria for 
schizophrenia or schizoaffective disorder.  These studies suggest that the risk for 
schizophrenia and spectrum disorders among populations with 22q11DS is 25 to 30 times 
that of the general population.  By comparison, research has not provided comparable 
evidence of an elevated risk for schizophrenia among individuals with other clearly 
identified genetic syndromes (Bassett & Chow, 1999).  Studies investigating the presence 
of 22q11 deletions in schizophrenic populations have yielded rates between 1% and 6%, 
representing a 40-240 fold increase over the rate of 22q11.2 deletions in the general 
population (Horowitz, Shifman, Rivlin, Pisante, & Darvasi, 2005; Karayiorgou et al., 
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1995; Usiskin et al, 1999; Yan et al., 1998).  These findings represent the strongest link to 
date between vulnerability to schizophrenia and a known genetic anomaly. 
Cognitive functioning in 22q11DS.  Recent studies of the cognitive and 
educational abilities of children and adolescents with 22q11DS report significant 
impairment in intellectual ability, with a mean Full-Scale IQ around 70 (Bearden et al., 
2001; Eliez et al., 2000; Lewandowski et al., 2007; Swillen et al., 2000).  Early language 
delays have often been reported, although later cognitive deficits more closely resemble 
nonverbal learning deficits, including relative strengths in reading and verbal tasks 
(Swillen et al., 1999; Lewandowski et al., 2007), and relative weaknesses in visuo-spatial 
abilities, arithmetic, and object perception (Swillen et al., 1999; Swillen et al., 2000; 
Bearden et al., 2001; Henry et al., 2002).  Children and adolescents with 22q11DS also 
tend to show a pattern of relative strengths in the areas of word knowledge, factual 
information, and understanding of concrete situations, and deficits in the areas of visual-
spatial memory, non-verbal reasoning, and perceptual motor skills (Eliez et al., 2000; 
Swillen et al., 2000).  Furthermore, recent findings suggest that nonpsychotic patients 
with 22q11DS exhibit specific deficits in prefrontally-mediated cognitive functioning 
including executive functioning, working memory, attention, and abstract and social 
thinking (Henry et al., 2002; van Amelsvoort et al., 2004; Lewandowski et al., 2007).  
Moreover, these deficits are not simply a function of general intellectual deficits, as they 
continue to account for significant variance over and above the effects of IQ (Bearden et 
al., 2004; Lewandowski et al., 2007).  
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Cognitive deficits in patients with 22q11DS do not appear to be related to the 
major physical anomalies associated with the syndrome (Bearden et al., 2001), as the 
same range of cognitive developmental outcomes is seen in children with and without 
cardiac defects and palate anomalies (Swillen et al., 2000).  This finding suggests that 
deficits in intelligence and other delays are primarily associated with neurodevelopmental 
consequences of the 22q11 deletion itself, and are not secondary to physical 
manifestations or therapeutic interventions associated with the disorder (Shprintzen, 
2000; Gerdes et al., 1999; Swillen et al., 2000).   
Behavioral characteristics in 22q11DS.  Studies of social and behavioral profiles 
in children and adolescents with 22q11DS have found elevations in social difficulties, 
and generally high rates of problem behaviors using observational and questionnaire data.  
Studies using the CBCL indicate that internalizing difficulties exceed externalizing 
difficulties, with elevations on the social problems, withdrawn, attention problems, and 
thought problems scales (Swillen et al., 1997; Swillen et al., 1999; Swillen, Devriendt, 
Ghesquiere, & Fryns, 2001).  Additionally, a study of 2 to 18-year-olds reported that this 
pattern of elevations is conserved across age groups (Swillen et al., 1999).  These 
findings are consistent with an earlier report based on observational and interview data by 
Golding-Kushner, Weller, and Shprintzen (1985), who found that children with 22q11DS 
exhibited “bland affect,” minimal facial expression, monotone voice, little disruptive 
behavior, and social problems that ranged from impulsivity to shyness.  This pattern of 
behavioral and social characteristics is not merely reflective of behavioral profiles of 
children with low IQ and language difficulties.  An investigation of behavior in 22q11DS 
23 
 
patients and children with low IQ and language disabilities without an identified genetic 
abnormality found that the 22q11DS patient group exceeded the comparison group on 
withdrawal, but were significantly lower than the comparison group on aggressiveness 
(Swillen et al., 2001). 
As might be expected based on the social, behavioral, and cognitive difficulties of 
children with 22q11DS, patients exhibit increased rates of childhood psychopathology.  
Lewandowski et al. (2007) reported significantly more DSM-IV disorders in children 
with 22q11DS (62%) than in control participants (32%).  Additionally, groups differed on 
ratings of Global Assessment of Functioning (Endicott, Spitzer, Fleiss, & Cohen, 1976), 
with control participants functioning significantly better overall.  Despite the overall 
group differences in clinical diagnoses, there were no significant differences between the 
groups in terms of percentages of participants receiving mental health treatment 
(22q11DS group = 30%; control group = 28%).  Commonly reported diagnoses in 
children with 22q11DS include AD/HD (most commonly inattentive type), phobia, 
depression, and autism spectrum disorders (Niklasson, Rasmussen, Oskarsdottir, & 
Gillberg, 2005; Lewandowski et al., 2007; Swillen et al., 1997), with rates of AD/HD, 
anxiety, and mood disorders as high as two to three times that of the general population 
(Murphy, 2002)   
22q11DS, COMT, and schizophrenia. As noted above, the gene that codes for 
COMT maps to the commonly deleted region in people with 22q11DS (Grossman et al., 
1992).  As a result, patients with 22q11DS have only one copy of this gene.  It is 
presumed that functional variation in enzyme activity based on the Val158Met 
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polymorphism in people hemizygous for the COMT gene follows a similar pattern to that 
seen in non-deleted individuals.  However, it is not clear the extent to which Val158Met 
functionally alters enzyme activity in this population.  That is, in people with two copies 
of the COMT gene, the Val/Val genotype is associated with a four-fold increase in 
COMT activity compared to people with the Met/Met genotype.  The precise increase in 
enzyme activity in people with the Val/0 genotype compared with people with the Met/0 
genotype has not been described.  In addition to findings that indicate that 22q11DS is 
associated with cognitive impairment in general, and that deficits may be especially 
pronounced in prefrontally-mediated domains, a recent study of cognitive functioning 
within this population reported that Val-hemizygous patients performed significantly 
worse on prefrontally-mediated tasks compared to their Met-hemizygous counterparts 
(Bearden et al., 2004).  However, both groups performed below the level that would be 
expected in a healthy population, with z scores on most tasks and on an executive 
function composite ranging from -0.5 to approximately -1.3 in the Met group, and less 
than -1.0 to approximately -1.6 in the Val group.  This indicates that, while 22q11DS 
patients with the Met allele performed better than patients with the Val allele, both 
groups exhibited deficits compared to the tasks’ normative samples.  Since executive 
dysfunction has been associated with patients with schizophrenia, as well as with people 
identified as high-risk based on family history or psychometric identification, and since 
patients with 22q11DS exhibit highly elevated rates of psychosis in adulthood (although 
far less than 100%), the Val158Met polymorphism may help refine identification of 
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patients with 22q11DS who are at especially elevated risk for the development of 
schizophrenia.  
22q11DS as a genetic high-risk sample.  Recent findings have suggested that the 
22q11 deletion may provide a risk marker for schizophrenia and may even represent an 
etiologically specific subtype of the disorder (Bassett & Chow, 1999; Bassett et al., 1998, 
Gothelf et al., 1997; Murphy et al., 1999).  Alternatively, 22q11DS may provide a more 
general contribution toward the neuromaldevelopment associated with vulnerability to 
schizophrenia, as the core clinical features of schizophrenia do not appear to differ 
between individuals with and without 22q11DS (Bassett et al., 2003).  Furthermore, the 
medical consequences of 22q11DS may provide additional disruption of 
neurodevelopment.  For example, perinatal hypoxia, which is associated with cardiac 
lesions found in 22q11DS, could contribute to the risk for schizophrenia (Cannon et al., 
2000).   
22q11DS provides a unique environment for the investigation of neurocognitive 
and genetic markers of vulnerability to schizophrenia and related disorders as patients 
have a strikingly increased risk for the development of psychosis, which is presumably 
influenced by the deletion of a specified 1.5 Mb genetic region.  The location of the 
COMT gene within the commonly deleted region in 22q11DS, together with findings of 
increased schizotypy and schizophrenic-like neurocognitive deficits in persons with the 
Val/Val or Val/0 genotypes, suggests that this is a promising area for research into the 
relationship between COMT, 22q11DS, and risk for schizophrenia.  It should be noted 
that there are a number of other genes in the commonly deleted region in 22q11DS that 
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have been associated with schizophrenia, which likely have complex interactions with 
COMT.  While COMT and the Val158Met functional polymorphism appear to be 
associated with prefrontal cognitive functioning, social and behavioral difficulties, and 
symptom measures associated with schizophrenia, it is likely that other genes and SNPs 
in the 22q11.2 region are associated with vulnerability to schizophrenia as well, either 
independently or in combination with COMT.  Haplotype investigations such as those 
reported by Shifman et al. (2002) and Funke et al. (2005) may help identify combinations 
of alleles that are associated with vulnerability, and may help refine our understanding of 
the complex associations amongst these markers.  Unlike most high-risk approaches to 
the study of schizophrenia, 22q11DS provides a clear genetic starting point for the 
investigation of indicators of vulnerability and their associations with genetic variation. 
Goals and Hypotheses 
The goal of the present study was to examine the relationship among 
schizophrenic-like neurocognitive functioning, social and behavioral dysfunction, and 
COMT genotype in a sample of children with 22q11DS.  Studying children and 
adolescents permits the examination of psychopathology and schizophrenic-like cognitive 
and behavioral deficits absent the consequences of schizophrenia, such as medication 
effects, hospitalization, or stigma, and ultimately allows for the prospective study of risk.  
It is hypothesized that a) 22q11DS participants with the Val allele will perform worse on 
neurocognitive measures of prefrontal functioning than 22q11DS participants with the 
Met allele, but will not differ on non-prefrontal measures, b) participants with the Val 
allele will exhibit more behavioral dysfunction consistent with those identified in 
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children who later develop schizophrenia then participants with the Met allele, c) 
participants with the Val allele will exhibit more psychopathology than participants with 
the Met allele, especially in domains associated with reduced executive control such as 
AD/HD while participants with the Met allele will exhibit more psychopathology in 
mood and anxiety domains, and d) the COMT haplotype described by Shifman et al. 
(2002) will be associated with both schizophrenic-like neurocognitive deficits and with 
psychosocial difficulties that have been associated with schizophrenia and schizotypy.  
This study represents the first work to date to examine the effects of a COMT haplotype 
on neurocognitive functioning and psychopathology in nonpsychotic 22q11DS patients. 
Hypothesis 1: Patients with the Val allele will perform worse than patients with 
the Met allele on measures of sustained attention, working memory, and executive 
functioning.  The two groups will not differ significantly on measures of general 
intelligence or achievement, or on a task of verbal learning and memory.  It was 
predicted that 22q11DS patients with the Val allele would perform worse than 22q11DS 
patients with the Met allele on tasks that are believed to tap prefrontal functioning, but 
not on tasks that measure general fund of knowledge, academic achievement, or verbal 
learning.  It should be noted that the average IQ of children with 22q11DS is 
approximately 70, which is two standard deviations below the mean for the general 
population.  Thus, while 22q11DS patients with the Val allele were hypothesized to 
perform worse than their Met allele peers, all children are expected to exhibit deficits in 
cognitive functioning in all domains assessed, including intelligence, academic 
achievement, sustained attention, working memory, and verbal learning. 
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 Hypothesis 2: Patients with the Val allele will exhibit higher rates of behavioral 
and social difficulties than patients with the Met allele in terms of social isolation and 
withdrawal.  Patients with the Met allele will exhibit increased levels of internalizing 
difficulties such as anxiety and affective problems.   Participants with the Val allele are 
expected to exhibit deficits similar to those seen during premorbid development in 
patients who later develop schizophrenia.  Conversely, patients with the Met allele are 
expected to exhibit more difficulties in areas of affective dysregulation, including anxiety 
and depression.  As with cognitive measures, all participants were expected to exhibit 
difficulties socially and behaviorally.  As noted above, patients with 22q11DS often have 
medical difficulties that limit exertion and increase days in the hospital and away from 
peers, facial dysmorphologies, intellectual deficits and learning difficulties, and speech 
disorders, each of which may affect children’s behavior and social interactions.  
Additionally, these difficulties would be expected to increase anxiety and affective 
dysregulation in patients.  However, within the 22q11DS group, it was predicted that 
patients with the Val allele would exhibit schizophrenic-like behavioral and social 
dysfunction such as social isolation, while patients with the Met allele would exhibit 
increased affective dysregulation.  
Hypothesis 3: Patients with the Val allele will exhibit higher rates of 
psychopathology than patients with the Met allele, specifically in areas that appear to be 
associated with deficits in prefrontal functioning, and greater deficits in global 
functioning.  Patients with the Met allele will exhibit more mood and anxiety symptoms 
than patients with the Val allele.   It was predicted that participants with the Val allele 
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will exhibit greater deficits in global functioning compared to their peers with the Met 
allele.  Additionally, it was predicted that the Val group would exhibit especially high 
rates of AD/HD, Oppositional Defiant Disorder, and conduct problems, which are 
associated with poor planning, poor working memory, or decreased behavioral inhibition.  
AD/HD has been hypothesized to be associated with difficulties in sustained attention, 
planning and sequencing, and behavioral inhibition – tasks that it was hypothesized the 
Val group would exhibit deficits on compared to the Met group.  Patients with the Met 
allele were hypothesized to exhibit greater symptoms of mood and anxiety disorders than 
patients with the Val allele, consistent with findings that the Met allele is associated with 
hyperresponsivity to negative stimuli in adults. 
Note that, while the incidence of psychotic disorders appears to be significantly 
elevated in adults with 22q11DS, psychosis was a rule-out criterion for recruitment into 
this study, as we are hoping to examine vulnerability to psychosis rather than correlates 
of the disorder itself.  Furthermore, early premorbid manifestations of vulnerability for 
schizophrenia typically do not involve positive symptoms of schizophrenia, but rather 
neurocognitive and behavioral manifestations.  Thus, we did not expect to find group 
differences in rates of psychotic disorders at this stage in the investigation.  However, 
longitudinal follow-up of our participants is planned and we expect to see psychotic 
disorders emerge in a subset of our participants as they enter adolescence and adulthood.   
Hypothesis 4: Patients with the COMT haplotype described by Shifman et al. 
(2002) will exhibit more neurocognitive deficits and more psychopathology than patients 
without the COMT haplotype.  The COMT haplotype described by Shifman et al. (2002), 
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which includes the Val allele, was found to be more predictive of schizophrenia than the 
Val158Met polymorphism alone.  Additionally, recent reports have suggested that this 
haplotype is also associated with bipolar disorder – another disorder that may be over-
represented in patients with 22q11DS.  However, as of the writing of this paper, this 
haplotype has not been examined in patients with 22q11DS, or in a high-risk group of 
nonpsychotic individuals.  Since the genotype involves polymorphisms in the COMT 
region, COMT has been associated with prefrontal cognitive performance, and people 
identified as at-risk for the development of psychosis perform worse than control 
participants on prefrontally-mediated tasks, it was hypothesized that children with this 
haplotype will both perform worse on prefrontally-mediated cognitive tasks and will 
exhibit more psychopathology than children without the haplotype.  
 
CHAPTER II 
METHOD 
 
 
 
Participants  
 The sample consisted of 27 patients with 22q11DS recruited through the 
Department of Genetics at Wake Forest University School of Medicine (WFUSM).  
Investigations of the COMT polymorphism and neurocognitive and behavioral symptoms 
in children with 22q11DS have detected group differences with sample sizes similar to 
that of the present study (Bearden et al., 2004; Bearden et al., 2005), and pilot work from 
our lab suggests that the present sample is sufficient.  In previous samples of participants 
without a 22q11 deletion (e.g. Bruder et al., 2005; Malhotra et al., 2002) approximately 
17% of participants had the Met/Met genotype, 44% had the Val/Met genotype, and 38% 
had the Val/Val genotype, which represents allele frequencies of approximately 39% Met 
and 61% Val.  This is consistent with findings of allele frequency in samples of 
participants with 22q11DS (Bearden et al., 2004; Bearden et al., 2005).  Therefore, it was 
expected that these proportions would be approximately the same in the present sample 
of patients with 22q11DS.  Indeed, the allele frequency in the present sample was 48% 
Met and 52% Val, X2 = 1.88, ns, which is consistent with previous findings and indicates 
that the present sample is representative of the general population and patients with 
22q11DS in terms of allele distribution.  
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The Val and Met groups did not differ on age at assessment, level of education, 
ethnicity, sex, parental SES, or global adjustment (see Table 1).  All participants were 
recruited by a Medical Geneticist and a Licensed Genetics Counselor and were seen in 
the Pediatric Medical Genetics clinic at WFUSM as part of ongoing treatment associated 
with the 22q11DS.  22q11.2 deletions were confirmed using fluorescence in situ 
hybridization (FISH).  All patients of the Genetics Clinic between the ages of 6 and 16 
with an identified 22q11 deletion were invited to participate in the study.  Consent was 
obtained from the parent or legal guardian of each participant.   
Materials   
Neurocognitive measures evaluating sustained attention, executive functioning, 
verbal working memory, intelligence, and achievement were administered.  Sustained 
attention was assessed using the Continuous Performance Test (CPT; Cornblatt, 
Lenzenweger, & Erlenmeyer-Kimling, 1989), executive functioning was assessed using 
the Wisconsin Card Sorting Test (Heaton et al., 1993), and verbal working memory was 
assessed using the California Verbal Learning Test-Children’s Version (CVLT-C; Delis, 
Kramer, Kaplan, & Ober, 1994).  Intelligence was measured using the Wechsler 
Intelligence Scale for Children, 3rd and 4th Editions (WISC-III; Wechsler, 1991; WISC-
IV; Wechsler, 2003), and academic achievement will be measured using the Wechsler 
Individual Achievement Test, 2nd Edition (WIAT-II; Wechsler, 2001).  Research on 
cognitive deficits in individuals with schizophrenia and schizotypal personality disorder 
and people identified as at-risk based on psychometric identification or first-degree 
relative status have found deficits in attention, executive functioning, and verbal working 
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memory using these measures or comparable adult versions (Aloia et al., 1996; Bergman 
et al., 1998; Cornblatt & Erlenmeyer-Kimling, 1985; Cornblatt et al., 1988; Erlenmeyer-
Kimling et al., 2000; Erlenmeyer-Kimling, 2000; Gold & Harvey, 1993; Gooding, 
Kwapil, & Tallent, 1999; Lenzenweger & Dworkin, 1998; Lyons et al., 1995; 
Nuecheterlein, 1983; Saykin et al., 1991).  Behavioral functioning was assessed using the 
Child Behavior Checklist (CBCL; Achenbach, 2001), and social functioning was 
assessed using the Social Skills Rating Scale (SSRS; Gresham & Elliot, 1990).  
Childhood psychopathology was examined using the Computerized Diagnostic Interview 
Schedule for Children (C-DISC; Shaffer, Fisher, Lucas, Dulcan, & Schwab-Stone, 2000). 
 Continuous Performance Test.  The CPT assesses the ability to focus and sustain 
attention (Cornblatt et al., 1988).  Participants were assessed with the Identical Pairs (IP) 
and AX versions of the test.  In the CPT-IP, participants were presented with a series of 
numbers or shapes on a computer screen, and instructed to lift their fingers off a 
computer mouse if they saw identical stimuli appear on consecutive trials.  Participants 
were tested on four IP conditions involving numbers or shapes, and stimuli which were 
presented “fast”, meaning that they appeared for less time on the screen (50ms), or 
“slow” meaning that they appeared for more time on the screen (150ms).  The AX 
version involved the presentation of single digits on the screen.  Participants were 
instructed to lift their fingers off the mouse button when they saw the number eight 
immediately preceded by the number two.  In addition to assessing attention, the AX 
version also taps the ability to gate or inhibit incorrect responses. Prior to the first IP 
condition and the AX condition, participants completed a practice session using cards.  
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This allowed participants to become familiar with the types of stimuli they would be 
encountering, and allowed the experimenter to determine whether or not participants 
understood the instructions.  Participants then completed a practice session on the 
computer, followed by the test sessions.  Scores were reported in terms of d’, a signal 
detection index that is relatively unaffected by response bias (i.e. over- or under-
responding).  The four CPT-IP conditions were combined to form a single CPT-IP 
composite score.  The CPT has been normed for use with individuals from a wide range 
of ages and ability levels and reports good reliability (Cornblatt et al., 1988; Heaton et al., 
1993).  Cornblatt et al. (1985) found that the CPT-IP was an effective predictor of the 
development of schizophrenia in a genetically at-risk sample.   
 The Wisconsin Card Sorting Test.  The WCST is widely used to assess executive 
functioning (Chelune & Baer, 1986).  Participants viewed four cue cards on a computer 
screen containing one to four colored shapes that matched keyboard stickers placed on 
four adjacent computer keys.  Participants also saw a single card that they were to match 
to one of the four cue cards.  At each turn the correct matching rule may be color, 
number, or shape, with only one of the categories being correct per trial.  The participant 
was instructed to match the card to one of the four cue cards, but was not told the correct 
matching rule.  Participants were given both visual and auditory feedback (either RIGHT 
or WRONG).  The participant must incorporate the feedback from each turn to correctly 
place the next card.  The sorting rule (color, number, or shape) changed after ten 
consecutive correct responses without the participant’s knowledge, requiring him or her 
to apply a different sorting rule.  Indices used in the present study include perseverative 
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errors, or failure to switch sorting rules despite feedback indicating that the old rule is no 
longer effective, nonperseverative errors, and conceptual level response, an indicator that 
an understanding of the sorting rule has been achieved.  Patients with schizophrenia and 
individuals presumed to be at risk for schizophrenia exhibit deficits on WCST 
performance (e.g., Goldberg & Weinberger, 1988; Gooding et al., 1999).   
The California Verbal Learning Test-Children’s Version.  The CVLT-C is a test 
of verbal learning and memory designed to assist in the identification of impairments 
associated with, or secondary to, learning disorders and neurological and psychiatric 
problems in children aged 5 to 16 years.  This measure was developed and normed for 
use with children, and has good reliability and validity (Delis et al., 1994).  Lists of words 
presented as shopping lists were read aloud, and participants were asked to recall as many 
words as possible.  The first list (List A) consisted of 15 words, each belonging to one of 
three semantic clusters – fruits, clothing, and playthings.  The list was read once and the 
participant was asked to recall as many words as he or she could.  List A was repeated 
four more times, with recall assessed after each trial.  Next, a distracter list (List B) was 
read, consisting of 15 new words, each belonging to one of three semantic clusters, one of 
which was the same as List A (fruits), and two of which were new (sweets and furniture).  
The participant was asked to recall as many words from List B as he or she could.  The 
participant was then asked to recall as many words from List A as possible.  This task 
was followed by a cued-recall task in which the participant was asked to recall as many 
words from List A as possible within each of the three semantic clusters.  The participant 
was then given a twenty-minute break during which a non-verbal task (WCST) was 
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performed.  Following this long delay, the participant was asked to perform both free-
recall and cued-recall tests of List A.  Finally, a recognition task was administered in 
which a list of 45 words was read.  The participant was asked to respond affirmatively 
only when he or she heard a word from List A.  The word list consisted of words from 
List A, words from List B, and previously untested words, some of which were 
semantically related to the clusters from List A and B.   
The CVLT-C produces a number of indices that can be grouped into the broad 
domains of recall, learning strategies, and recognition.  In the present study, recall was 
measured using scores from the five immediate recall trials for list A, the number of 
words correct on the first list A trial, and scores on the short-delay and long-delay free 
and cued recall conditions.  Learning strategies were evaluated using semantic and serial 
clustering scores, with semantic clustering indicating a more advanced learning style.  
Lastly, recognition was examined using scores from the recognition task.  Comparisons 
between recognition and recall can be made in order to evaluate whether problems with 
verbal memory are at the level of encoding or retrieval.  For example, low scores on 
recall tasks followed by a relatively higher score on the recognition task may be 
indicative of a retrieval problem, as the words are apparently encoded properly.  
However, poor scores on recall and recognition may indicate an encoding problem, as the 
words are not recognized, even with prompting.  While there is no literature to date 
examining the relationship between CVLT-C performance and schizotypy in children, 
patients with schizophrenia exhibit impairment on verbal learning tasks, as do adults with 
schizotypal personality disorder (Bergman et al., 1998; Hill, Beers, Kmiec, Keshavan, & 
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Sweeney, 2004). However, as noted above, children with 22q11DS tend to show relative 
strengths in verbal, as opposed to nonverbal, performance. 
The Wechsler Intelligence Scale for Children, 3rd and 4th Editions.  The WISC-III 
and the WISC-IV are widely used intelligence tests for children.  The WISC-III battery 
consists of ten subtests that produce individual scaled scores and combine to yield a 
Verbal IQ score, a Performance IQ score, and a Full-Scale IQ score.  The mean for 
Verbal IQ, Performance IQ, and Full Scale IQ is 100 with a standard deviation of 15.  
Additionally, two extra subtests can be administered and combined with the 10 basic 
subtests to yield four factor scores, including Verbal Comprehension, Perceptual 
Organization, Freedom from Distractibility, and Processing Speed.  These scores are also 
based on a mean of 100 and a standard deviation of 15.  The WISC-IV consists of ten 
subtests that yield a Full Scale IQ score and four scale scores: Verbal Comprehension, 
Perceptual Organization, Processing Speed, and Working Memory.  While the WISC-III 
and WISC-IV scale scores are not made up of identical subtests, the Verbal 
Comprehension scale is comparable to Verbal IQ (r = .87), the Perceptual Organization 
scale is comparable to Performance IQ (r =.74), and the Full Scale IQ scores from the 
two tests are comparable (r = .89) (Wechsler, 2003).  Participants assessed after January, 
2004 were administered the WISC-IV, while prior to 2004 participants were administered 
the WISC-III.  While it would have been preferable to maintain use of the WISC-III 
throughout data collection, the benefit of providing useful psychoeducational testing 
reports to families was a major incentive to participant recruitment.  Together with the 
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comparability of the two versions of the test, it was decided that use of the current 
version of the WISC was appropriate.  
The Wechsler Individual Achievement Test, 2nd Edition.  The WIAT-II is a widely 
used test of academic achievement.  The present study employed six subtests that assess 
word reading, phonetic decoding, and reading comprehension in the domain of Broad 
Reading, computational skills and math reasoning in the domain of Broad Mathematics, 
and spelling achievement.  The testing yields scaled scores on each of the subtests and the 
broad domains.  These scores are normed to a mean of 100 and a standard deviation of 
15.   
Computerized Diagnostic Interview Schedule for Children.  The C-DISC is a 
semi-structured interview that was administered to each participant’s parent or primary 
caregiver in order to assess psychopathology in the participant.  The C-DISC is based on 
the DSM-IV (American Psychiatric Association, 2001) criteria for mental disorders, and 
is designed to address specific symptoms that must be evaluated in order to determine 
diagnostic status.  The interview contains a number of modules that assess most disorders 
described by the DSM-IV.  The present study assessed Mood Disorders, Anxiety 
Disorders, Psychotic Disorders, Attention Deficit /Hyperactivity Disorder (AD/HD), 
Oppositional-Defiant Disorder, and Conduct Disorder.  None of the parents reported that 
their children used substances; therefore, the substance use disorders modules were not 
administered.  
The Child Behavior Checklist. The CBCL is a 118-item questionnaire designed to 
tap childhood functioning across a wide array of areas, including competencies and 
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specific behavioral and emotional problems in children and adolescents ages 6-18.  
Questionnaires are completed by a parent, guardian, or close relative of the child who 
knows him or her well.  Items are keyed as 0 (not true), 1 (somewhat or sometimes true), 
or 2 (very true or often true) based on the respondent’s knowledge of the child currently 
or within the past 6 months.  Items are entered into a computer scoring software package 
that generates T-scores, with a mean of 50 and a standard deviation of 10.  The scales that 
are generated include: Activities, Social, School, and a Total Competency score within 
the Competency domain, and Withdrawn, Somatic, Anxious/Depressed, Social, Thought 
Problems, Attention, Delinquent, Aggressive, Internalizing, Externalizing, and a Total 
Problem score within the Problem domain.   
Scores from the CBCL have been used to measure functioning in children with an 
array of psychiatric disorders, and have been associated with premorbid behavioral 
difficulties in children who later develop schizophrenia.  A study of 23 adolescents with 
early onset schizophrenia found that children who went on to develop psychosis in 
adolescence exhibited higher problem scores on the CBCL compared to healthy children, 
and specific deficits in social competencies and school problems when compared to 
adolescents with anorexia nervosa (Muratori, Salvadori, D’Arcangelo, Viglione, & 
Picchi, 2005).  Additionally, early and persistent behavioral problems through childhood 
as measured by the CBCL have been associated with more severe symptoms in adult 
patients with schizophrenia based on retrospective report (Rossi et al., 2002).  In first-
degree relatives, scores on the CBCL have been associated with later development of 
psychosis.  In particular, high scores on the withdrawn, delinquent, and aggressive 
40 
 
behavior scales in nonpsychotic adolescents predicted onset of schizophrenia during 
adulthood (Miller, Byrne, Hodges, Lawrie, & Johnstone, 2002). 
The Social Skills Rating Scale.  The SSRS is a questionnaire measure that assesses 
social functioning including social skills and problem behaviors in children and 
adolescents ages 3-18.  The competency scales measure behaviors in the domains of 
Cooperation, Empathy, Assertion, Self-Control, and Responsibility, while the problem 
scales assess behaviors that interfere with appropriate social functioning and 
development, including aggression and poor temper control (Externalizing), sadness and 
anxiety (Internalizing), and fidgeting and impulsive acts (Hyperactivity).  Raw scores are 
provided on the subscales, and standardized scores are generated for the scale scores 
based on means of 100 and standard deviations of 10.  Standardized scores are calculated 
based on separate norms for boys and girls.   
Genotyping.  The COMT genotype was determined by restriction fragment length 
polymorphism (RFLP). A 109 base pair polymerase chain reaction product was obtained 
in 30-40 cycles with an annealing temperature of 55°C with the use of primers 5’-
CTCATCACCATCGAGATCAA and 5’-CCAGGTCTGACAACGGGTCA described in 
detail by Lachman et al., 1996. The Val and Met alleles were discriminated by digesting 
the PCR product with NlaIII at 37°C overnight and separated by agarose 
gel electrophoresis (3.5 - 4%).  The Val allele (uncut) was identified by digestion 
products at 87 and 22 base pairs, while the Met allele (cut) was identified by digestion 
products at 69, 22, and 18 base pairs.  These analyses were conducted at WFUBMC by a 
molecular geneticist or advanced lab technician experienced in PCR.   
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Procedure 
Participants were assessed individually at Wake Forest University Baptist 
Medical Center and the University of North Carolina at Greensboro Department of 
Psychology.  DNA was collected through blood draw or sputum collection, which was 
performed by a pediatrician.  The neurocognitive measures and interviews were 
administered by a licensed clinical psychologist or trained graduate students in clinical 
psychology under the supervision of a licensed clinical psychologist.  The administration 
of the assessment battery requires approximately 4 to 5 hours, so the testing was broken 
up into two or three sessions to minimize the effects of participant fatigue on the 
assessment results.  In the event that a participant was assessed using the WISC-III, 
WISC-IV, or WIAT-II within the past year, the results from the previous assessments 
were obtained.  Control participants received $50 upon the completion of the testing 
sessions.  Additionally, all participants received summary reports of their assessment 
results.  
 
CHAPTER III 
RESULTS 
 
 
Hypothesis 1:Neurocognitive and Intellectual Functioning   
The Val and Met groups were compared on measures of sustained attention, 
working memory, executive functioning, verbal learning, intelligence, and academic 
achievement using t-tests.  Additionally, effect sizes were calculated using Cohen’s d.  
Cohen’s d measures the magnitude of an observed effect in units of standard deviation 
independent of sample size, providing a complement to statistical significance testing.  
According to Cohen (1988), d = .2 indicates a small effect size, d = .5 indicates a medium 
effect size, and d = .8 indicates a large effect size.  Group means, comparisons, and effect 
sizes on the CPT, WCST, and CVLT-C are reported in Table 2.  Groups did not differ 
significantly on any of the CPT indices.  However, the effect size analyses of the CPT-IP 
scores showed a moderate effect of genotype on performance with the Val group 
performing better (d =.-57).  Conversely, a moderate effect of genotype on CPT-AX 
performance was found, with Met participants performing better (d = .60).  It should be 
noted that both groups performed near the floor on the CPT-IP, suggesting that the 
difficulty of the task may have been too great for the subjects.  No group differences were 
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found on the WCST indices, and effect sizes were small.  Finally, groups did not differ 
on any of the CVLT-C indices, and effect sizes were small at best.   
Group means, comparisons, and Cohen’s d scores on the WISC are summarized 
in Table 3.  The Met group scored significantly higher than the Val group in terms of Full 
Scale IQ (t = 2.19, p < .05; d = .86) and Verbal IQ scores (t = 2.18, p < .05; d = .86), but 
did not differ on the Performance Scale scores.  Groups differed on the Working Memory 
and Processing Speed factor scores, with the Met group performing significantly better 
than the Val group (t = 2.40, p < .05 and t = 2.09, p < .05, respectively).  Comparisons on 
these measures indicated large effect sizes for both the Working Memory and the 
Processing Speed factors (d =1.0 and .85, respectively).  Finally, in terms of subtest 
scores, the Met group performed significantly better than the Val group on Symbol 
Search (t = 2.36, p < .05) and Picture Arrangement (t = 3.56, p < .01), and showed trends 
in the same direction on the Arithmetic and Picture Completion subtests (t = 1.98, p < .10 
and t = 1.94, p < .10, respectively).  Furthermore, the Symbol Search, Arithmetic, Picture 
Completion, and Picture Arrangement subtests showed large effect sizes, and the 
Similarities, Vocabulary, Information, and Digit Span subtests showed moderate effect 
sizes.   
Scores from the WIAT-II are presented in Table 4.  The six subtests administered 
and the Broad Reading and Broad Math Clusters were examined.  Groups did not differ 
significantly on the Broad Reading Cluster, any of the reading subtests, or the Spelling 
subtest.  However, the Met group scored significantly higher than the Val group on the 
Math Reasoning subtest (t = 2.78, p < .05), and showed a trend toward higher scores on 
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the Broad Mathematics Cluster (t = 1.96, p < .10).  In terms of effect size, examination of 
the Math Reasoning subtests indicated that there was a large group effect, and moderate 
group effects were found on the overall Broad Reading Cluster, the Word Reading and 
Reading Comprehension subtests, the Spelling subtest, the Broad Mathematics Cluster, 
and the Numerical Operations subtest.   
Hypothesis 2: Social and Behavioral Functioning 
 Scores from the CBCL Competency and Problem Scales are presented in Table 5.  
The overall Competency Total score, the overall Problem Total score, and the ten 
problem subscale scores were compared using t-tests.  The Val group exhibited higher 
problem scale scores on the Anxious/Depressed and Aggressive scales, but did not differ 
from the Met group in terms of Competency, Total Problems, or any of the other problem 
scores.  However, a moderate effect size was found on the Total Competency score, with 
the Val group scoring lower in total competency.  Moderate effect sizes were also found 
on the Withdrawn, Internalizing, and Externalizing problem subscales, with the Val 
group exhibiting higher problem ratings.  
 Measures of social functioning based on SSRS ratings are presented in Table 6.  
T-tests showed that patients with the Val allele were rated lower than patients with the 
Met allele on Assertion (t = 3.23, p<.01), and showed a trend toward poorer functioning 
based on the Total Skills composite (t = 1.74, p<.10).  Additionally, a large group effect 
size was found on the Assertion subscale and moderate effect sizes were found on the 
Responsibility and Skills Total scales.  No differences were found on the Externalizing, 
Internalizing, Hyperactivity, or Total Problem scales.   
45 
 
Hypothesis 3: Childhood Psychopathology 
Val and Met groups were compared on measures of psychopathology based on 
scores on the C-DISC interview (see Table 7).  Overall functioning was examined using 
the GAF.  Participants’ scores were recorded dichotomously for each disorder (present or 
absent) except for AD/HD, which was recorded both dichotomously and continuously 
based on inattention symptom count and hyperactivity symptom count.  Groups were 
compared using Fisher’s Exact Test for percentage of participants who met criteria for a 
given disorder, any anxiety disorder, and any mood disorder.  Additionally, groups were 
compared using t-tests on measures of AD/HD symptoms, and on GAF scores.  Groups 
did not differ on any measure of psychopathology, AD/HD symptoms, or overall 
adjustment as measured by the Global Assessment of Functioning (Table 1). 
Hypothesis 4: Haplotype Analyses 
One 3-allele haplotype and three 2-allele haplotypes were described by Shifman 
et al. (2002).  The 3-marker haplotype included Val158Met, and the closely-linked 
rs737865 and rs165599 loci.  In all combinations of 2-marker haplotypes, as well as in 
the 3-marker haplotype, the G allele was found to be associated with risk for 
schizophrenia.  Individual genotype profiles were examined, and those patients who had a 
G-G or G-G-G haplotypes were considered haplotype-positive.  Seven of the 21 patients 
for whom data was available for all three loci were haplotype-positive – six patients were 
positive for a 2-marker haplotype, and one patient was positive for the 3-marker 
haplotype.  By comparison, haplotype examination of 19 control participants previously 
reported on (e.g. Lewandowski et al., 2007) for whom complete genetic data was 
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available showed that none had either a 2-marker or the 3-marker haplotype, Fisher’s 
Exact Test = .009.  Four patients had the COMT-rs165699 G-G haplotype, two patients 
had the COMT-rs737865 G-G haplotype, and one patient had the COMT-rs165599-
rs737865 G-G-G haplotype.  No patient had the rs737865-rs165599 G-G haplotype. 
Patients who were haplotype-positive were compared with patients who were 
haplotype-negative on measures of neurocognitive performance, IQ and achievement 
scores, and psychopathology.  Examination of cognitive functioning in patients with the 
2- and 3- marker haplotypes showed that haplotype-positive patients scored significantly 
worse on WCST non-perseverative errors (t = -3.18, p<.01), percent conceptual level 
response (t = -2.95, p<01), and a showed a trend toward fewer categories completed (t = -
2.04, p< .10) (see Table 8).  There were no significant group differences on any of the 
CVLT-C indices, or on the CPT-IP or CPT-AX measures based on t- test.  However, 
effect size analyses indicated that there was a small to moderate effect size in terms of 
CPT-AX scores in the expected direction (Cohen’s d = -.47).  Surprisingly, a moderate 
effect size was found in the opposite direction in terms of CPT-IP performance, with 
haplotype-negative patients performing worse than haplotype-positive patients (Cohen’s 
d = .54).  No significant differences emerged between groups in terms of CVLT-C 
functioning; however, moderate effect sizes were found on the Short Delay Free recall 
and the Long Delay Cued recall conditions, with haplotype-positive patients performing 
worse.   
Means and standard deviations from IQ and achievement testing are presented in 
Table 9.  In terms of IQ Scale scores, patients who were haplotype-positive exhibited 
47 
 
trends toward lower Full Scale IQ (t = -2.03, p< .10) and Verbal IQ (t = -1.89, p< .10).  
Patients who were haplotype-positive performed worse on the Working Memory and 
Processing Speed factors (t = -2.45, p< .05 and t = -2.32, p< .05, respectively), and 
showed a trend toward poorer performance on the Perceptual Organization factor (t = -
1.90, p< .10).  Large effect sizes were observed on the Full Scale IQ score, Verbal IQ 
score, all four Factor scores, and several of the subtests, including Digit Span, Coding, 
Vocabulary, Symbol Search, Arithmetic, Picture Completion, and Picture Arrangement.  
Additionally, moderate effect sizes were observed on the Performance IQ Scale score and 
most of the remaining subtests, including Similarities, Comprehension, and Information.  
The only subtests that showed small effects were Block Design and Object Assembly.  
All group differences were in the expected direction, with haplotype-positive patients 
scoring worse than haplotype-negative patients.  In terms of academic achievement 
testing with the WIAT-II, haplotype-positive patients scored significantly lower than 
haplotype-positive patients on the Numerical Operations subtest, and showed trends 
toward poorer scores on the Math Reasoning subtest and the Broad Mathematics Cluster.  
Effect size analyses showed large effects of group on the Broad Mathematics Cluster, and 
the Numerical Operations and Math Reasoning subtests.  A moderate effect size was 
found on the Word Reading subtest.  Again, all group differences were in the expected 
direction, with haplotype-positive patients scoring worse than their haplotype-negative 
peers.   
Scores from the CBCL and SSRS by group are presented in Tables 10 and 11.  
Haplotype-positive patients scored significantly lower on the CBCL Total Competency (t 
48 
 
= -2.79, p< .05) and on the SSRS Assertion scale (t = -2.97, p< .01).  Again, due to the 
small sample size in the haplotype-positive group, effect sizes were calculated in order to 
examine group differences on behavioral and social measures.  Large group effects were 
seen on the CBCL Competency scale and the SSRS Assertion scale, and moderate effect 
sizes were seen on the CBCL Withdrawn and Anxious/Depressed scales and on the SSRS 
Skills Total scale.   
Finally, descriptive information is provided separately for the one patient who 
was positive for the 3-marker haplotype described by Shifman et al. (2002) (Tables 12 
and 13).  In terms of cognitive functioning, this patient scored in the borderline mentally-
retarded range based on the WISC Full Scale IQ score, VIQ, and PIQ scores.  These 
scores are commensurate with the means within the 22q11DS patient group as a whole.  
In terms of WIAT-II scores, this participant scored more than one standard deviation 
below the mean on the Broad Reading cluster, and more than two standard deviations 
below the mean on the Broad Math cluster.  Again these scores are commensurate with 
22q11DS group means.  In terms of sustained attention and verbal learning and memory, 
this patient’s scores were more than one standard deviation below the 22q11DS group as 
a whole on the CPT-IP measure, and showed a trend in the same direction on the CPT-
AX measure.  Additionally, the patient scored at least one standard deviation below the 
22q11DS group on most of the CVLT-C indices.  Finally, in terms of social and 
behavioral functioning, this participant’s scores on the CBCL Withdrawn and 
Anxious/Depressed scales were more than one standard deviation above the 22q11DS 
group (indicating poorer functioning in these domains).  Conversely, this patient’s score 
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on the Attention problem scale was greater than one standard deviation below the 
22q11DS mean (indicating fewer attention problems). 
 
CHAPTER IV 
DISCUSSION 
 
 
 The present study examined the relationship of the COMT Val158Met 
polymorphism with neurocognitive functioning and childhood psychopathology in a 
sample of children and adolescents with 22q11DS.  It was hypothesized that prefrontally-
mediated cognitive functioning would be associated with genotype, with Val patients 
performing worse on tasks of executive functioning, working memory, and sustained 
attention than patients with the Met allele.  Additionally, it was hypothesized that 
genotype would not be associated with general intelligence or academic achievement, or 
performance on a nonprefrontally-mediated task of verbal learning and memory.  
Furthermore, it was predicted that children with the Val allele would be more likely to 
exhibit social and behavioral deficits associated with vulnerability to psychosis, and 
psychopathology associated with deficits of prefrontal control such as AD/HD and 
conduct problems.  It was further hypothesized that children with the Met allele would be 
more likely to exhibit psychopathology associated with hyperresponsivity to negative 
affect, such as mood and anxiety disorders.  Findings indicated that the COMT Val158Met 
polymorphism was associated with overall intellectual and academic functioning, and 
with deficits in working memory.  Additionally, the COMT Val158Met polymorphism was 
associated with social and behavioral functioning in children with 22q11DS.  While the 
present sample was not large enough to permit the examination of the effects of sex or 
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age on cognitive and behavioral functioning, group differences do not appear to be a 
function of sex or age as the groups did not differ on these variables.  The present study 
represents a preliminary investigation of the effects of a genetic variant on cognitive and 
behavioral functioning in children with a putative genetic vulnerability to schizophrenia.  
Additionally, this is the first study to date to examine a previously-reported COMT 
susceptibility haplotype in patients with 22q11DS. 
Cognitive Performance and COMT Genotype 
Comparisons of COMT genotype in patients with 22q11DS on measures of 
cognitive functioning indicated that, as expected, patients with the Val allele exhibited 
deficits on tasks measuring working memory and processing speed.  While significant 
differences were not detected on measures of sustained attention and executive 
functioning, the small sample size and moderate to large effect sizes on several indices 
suggest that the present study was underpowered to detect such differences in younger 
children.  In terms of intellectual functioning and academic achievement, patients with 
the Met allele scored higher on the Math Reasoning subtest of the WIAT-II.  
Additionally, moderate effect sizes were found on many of the WISC factors and 
subscales, and on all measures of the WIAT-II except pseudoword decoding.  Children 
with the Val allele on average performed significantly below standardized norms on all 
subtests and both available cluster scores of the WIAT-II, whereas children with the Met 
allele on average were not significantly below standardized norms in terms of Broad 
Reading, each of the reading subtests, and the spelling subtest.  In terms of verbal 
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learning and memory, groups did not differ on any index of the CVLT-C, indicating that 
these domains of functioning are not affected by COMT genotype. 
Group differences in terms of intelligence and academic achievement were not 
anticipated.  It is possible that, in patients with 22q11DS, the Met allele may be a marker 
of better overall cognitive functioning rather than better prefrontal functioning 
specifically.  This is consistent with findings of Barnett et al. (2007), who reported that 
COMT may have an effect on IQ variation.  However, the WISC Scale Scores are 
comprised of clusters of individual subtests which tap different aspects of intellectual 
functioning.  Children with the Val allele performed significantly worse than children 
with the Met allele on several subtests, and had mean scores that were observationally 
lower on each subtest.  While many of these differences were not statistically significant, 
they were combined to yield Factor and Scale Scores that were significantly different.  
Specifically, the factor scores from the WISC the showed the greatest group differences 
were the Working Memory and Processing Speed factors, indicating that, while overall 
IQ was lower in children with the Val allele, scores on the subtests that make up these 
two factors may have been especially impaired.   
The subtest that showed the greatest group difference was Picture Arrangement – 
a task that requires children to arrange cards in an order that tells a logical story.  This 
task requires attention to visual detail, social reasoning, cognitive flexibility, and working 
memory skills, as the task is facilitated by the ability to hold the content of the cards in 
memory and manipulate them in order to find the correct story.  Additionally, this task is 
timed, such that quicker correct solutions yield more points, making processing speed an 
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important component as well.  It should be noted that the group differences on this task 
do not appear to be a result of children with the Met allele performing especially well, 
but, rather, that children with the Val allele performed especially poorly.  The mean of 
the Met group on this task was 6.1 (sd = 2.4), while the mean of the Val group was 2.8 
(sd = 1.6).  When the subtest scores were averaged within groups, the mean subtest score 
across all subtests for the Met participants was 6.4 (sd = .67) and the mean subtest score 
for the Val participants was 4.6 (sd = .95).  Thus, the Met group’s scores on Picture 
Arrangement were commensurate with their scores in general, while the Val participants 
appear to have performed more poorly than would be expected based on their other 
scores, and showed a marked deficit compared to children in the general population, 
falling more than two standard deviations below the mean.   
Thus, while Full Scale and Verbal IQ scores differed between groups, there were 
specific domains of cognitive functioning that influenced these scores, including tasks 
that tap reasoning, working memory, and visual attention and processing speed.  While 
scores on tasks that tap general fund of knowledge such as information and Vocabulary 
also showed moderate effect sizes by group, these effect sizes were smaller, and were not 
significantly different.  Together, these findings suggest that patients with the Val allele 
exhibit general deficits in intellectual functioning, but more profound deficits in the 
domains of working memory and processing speed.   
Again, it was surprising that genotype did not appear to affect executive 
functioning as assessed by the WCST, and showed a moderate effect size in the opposite 
direction expected on the CPT-IP.  While it is possible that genotype does not affect 
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cognitive processing on the WCST, it is also possible that the children with 22q11DS in 
our sample were too young and/or cognitively compromised for significant group 
differences on these measures of prefrontal functioning to emerge.  Similarly, scores on 
the CPT-IP indicate that this task may also have been too difficult for children with 
22q11DS.  Within the 22q11DS group, d’ scores for both Val and Met groups were close 
to zero on all IP conditions, suggesting that neither group exhibited an adequate level of 
ability to meet the demands of the tasks.  Additionally, scores on the WCST and CPT-IP 
were not correlated with any other measure of cognitive functioning or academic 
achievement, suggesting that this measure is not tapping cognitive processes associated 
with any index of the WISC or the WIAT.  Thus, there may be a floor effect that is being 
observed within the 22q11DS group on these measures.   
Scores on the WISC and WIAT, assessment tools that are designed to detect a 
wide range of functioning and ability in children, may have been better suited to this 
sample in terms of detecting variability at the lower range of functioning.  Indeed, 
differences within the 22q11DS group were detected in several domains using these 
measures, and patterns of deficits in the Val group were in the domains that were 
expected.  These findings lend support to the possibility that the present assessments 
selected for executive functioning and sustained attention were not sensitive enough to 
detect variation in functioning at the lower end, as it would seem improbable to find 
deficits in general intellectual ability that are not accompanied by impairment in 
prefrontal cognitive functioning.  That is, if the Val allele is associated with poorer 
general intellectual functioning, it would be expected that it would also be associated 
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with poorer cognitive functioning in prefrontal domains.  Additionally, it should be noted 
that, due to the small sample size, the present study may not have had enough power to 
detect differences.   
It is important to note that, as a group, children and adolescents with 22q11DS 
perform poorly compared to healthy children on assessments of general intellectual 
ability and academic achievement, and on tasks of executive functioning and sustained 
attention.  This is based on normative data for these tasks, and previous work that has 
demonstrated that children with 22q11DS exhibit deficits in intellectual functioning and 
academic achievement compared to control participants, and deficits in sustained 
attention and executive functioning that exceed the level that would be expected based on 
IQ (Lewandowski et al., 2007).  While children with 22q11DS and the Met allele 
performed significantly better than their Val peers on intellectual ability and academic 
achievement, they were still significantly below the norm for children in the same age 
range on Verbal IQ, Performance IQ, Full Scale IQ, and mathematics achievement.  This 
suggests that differences in performance on the CPT-AX, WISC, and WIAT-II between 
the Val and Met groups is not simply a function of poorer overall functioning, but 
represents differential deficits that may help partial variance within groups with 
22q11DS.   
Behavioral and Social Functioning and COMT Genotype 
 It was hypothesized that the Val group would exhibit more behavioral problems 
such as withdrawal, aggression, and externalizing traits, and lower overall competency 
based on the CBCL, as the Val allele has been associated with deficits in planning and 
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consequencing, behavioral disinhibition, and social withdrawal.  Patients with the Val 
allele were rated as significantly poorer than their peers with the Met allele on the SSRS 
Assertion scale, and exhibited deficits in total Social Skills, as was hypothesized.  
Medium to large effect sizes were seen in terms of aggression, withdrawal, and 
externalizing problems, and overall competency, with patients with the Val allele 
showing more difficulties than patients with the Met allele.  These findings were not 
statistically significant, and we are thus unable to determine whether the lack of 
significance is due to lack of group differences or to low power. 
It should be noted that both groups were rated as being significantly impaired on 
overall competency, as well as on the Somatic, Social, and Attention problem scales.  
However, only children with the Val allele were more than one standard deviation above 
the mean on the Withdrawn, Anxious/Depressed, Internalizing, and Total Problem scales.  
This indicates that children with 22q11DS exhibit deficits compared to the general 
population on several indices of childhood behavioral functioning, and that, within this 
group, children with the Val allele have particular difficulties with behavioral and 
affective regulation.  Thus, patients with the Val allele exhibit increased behavioral 
difficulties and more social problems than patients with the Met allele, and these 
difficulties are in domains that have been associated with children who later develop 
schizophrenia.   
It was also predicted that the Met group would exhibit more anxiety, depression, 
and internalizing problems based on findings that the Met allele is associated with 
affective reactivity.  However, patients with the Met allele actually exhibited fewer 
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symptoms of anxiety and depression than patients with the Val allele.  Several factors 
may have affected this finding.  First, all measures of behavioral and social functioning 
were based on third-party report, which requires respondents to base their answers on 
observable behaviors or to guess at the child’s experiences.  This may be especially 
problematic in terms of estimating internalizing difficulties, as they are more difficult to 
see than externalizing behaviors or social deficits.  It is also possible that children with 
the Val allele are more behaviorally dysregulated and have poorer problem-solving and 
planning skills.  These difficulties may reduce a child’s ability to regulate affect and/or 
behavioral responses to difficult emotions including anger, frustration, or sadness, 
resulting in actual differences in anxiety and depression symptoms, or higher caregiver 
reports of these experiences based on observation.  Alternatively, the effects of the 
Val158Met polymorphism on affective processing may be dependent on maturational 
factors, such that these differences do not emerge until later adolescence or adulthood.  
Epidemiological studies indicate that the average age of onset of depression is during 
adolescence, and that rates of depression – especially in girls – increase sharply at this 
time (Costello, Mustillo, Erkanli, Keeler, & Angold, 2003).  This is likely associated with 
neurological and histochemical changes that occur around the onset of puberty, many of 
which involve the dopamine system (Angold & Costello, 2006).  Finally, it is possible 
that the Met allele is associated with hyperresponsivity to affective stimuli, as has been 
reported, but that these associations are not seen in patients with 22q11DS.  Amongst the 
many disruptions to development and neurological functioning, it is possible that the 
effects of COMT genotype on affective processing are not significant in this population 
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over and above the effects of other genetic or biological factors.  As the present sample 
matures, it may be beneficial to include self-report measures of anxiety and depression 
that can be completed by the participants themselves, and to examine changes in patterns 
of affective responding in order to better understand these associations.   
Childhood Psychopathology and COMT Genotype 
It was predicted that participants with the Val allele would exhibit deficits in 
global functioning compared to their peers with the Met allele.  Additionally, it was 
predicted that the Val group would exhibit especially high rates of AD/HD, ODD, or 
conduct problems, which are associated with poor planning, poor working memory, or 
decreased behavioral inhibition.  AD/HD has been associated with difficulties in 
sustained attention, planning and sequencing, and behavioral inhibition – tasks that it was 
hypothesized the Val group would exhibit deficits on compared to the Met group.  
Conversely, the Met allele has been associated with anxiety disorders, and symptoms 
involving hyperresponsivity to negative stimuli.  However, there were no differences in 
rates of any psychopathology between groups.  These findings do not appear to be due to 
low overall rates of psychological disorders in our young sample or underreporting by 
parents and caregivers of children with 22q11DS, as the rate of psychopathology was 
63% in the 22q11DS group – significantly higher than the rate of psychopathology in 
healthy control participants (Lewandowski et al., 2007).   
Note that, while the incidence of psychotic disorders appears to be significantly 
elevated in people with 22q11DS, psychosis was a rule-out criterion for recruitment into 
this study, as we are hoping to examine vulnerability to psychosis rather than correlates 
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of the disorder itself.  Thus, comparisons between the Val and Met groups in terms of 
psychosis were not able to be conducted.  However, longitudinal follow-up of our 
participants is planned, and we expect to see psychotic disorders emerge in a subset of 
our participants as they enter the window of risk.  Examination of the relationship 
between the Val158Met polymorphism and psychotic symptoms will be possible as our 
sample ages and psychotic symptoms begin to present themselves.  Furthermore, 
symptoms of psychopathology, subclinical psychotic symptoms, behavioral 
characteristics and social functioning prior to the onset of frank psychosis will continue 
to be examined as our cohort develops, permitting the investigation of these symptom and 
trait features with emergent psychosis.   
While it does not seem that the COMT Val158Met polymorphism was associated 
with diagnosis of childhood psychopathology in our 22q11DS sample, children with the 
Val allele exhibited more social and behavioral deficits than children with the Met allele 
in the present sample.  Thus, it may be that COMT genotype is more strongly associated 
with behavioral markers of underlying pathophysiology than with broad diagnostic 
categories in children with 22q11DS.  The present findings, along with a recent report by 
Bearden et al. (2005), found that the Val allele was associated with greater social 
problems, withdrawal, and delinquency in children with 22q11DS.  Such behavioral 
difficulties have been associated with premorbid adjustment in people who later develop 
schizophrenia based on retrospective reports and prospective follow-up (Bearden et al., 
2000; Cannon et al., 1997; Jones et al., 1994).  Thus, the COMT Val158Met polymorphism 
may be associated with behavioral dysfunction in children similar to the dysfunction seen 
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in premorbid schizophrenia, indicating that behavioral and psychosocial measures of 
dysfunction may be more strongly associated with the polymorphism that overt 
psychopathology in nonpsychotic children with 22q11DS.  Additionally, the mean age of 
the children in the present report is approximately 9.5 years.  As the present sample 
enters adolescence, more distinct patterns of psychopathology may begin to emerge. 
In terms of global functioning, it is surprising to note that there were no 
differences between the Val and Met groups in terms of GAF score, given the lower 
intellectual functioning and academic achievement scores, and increased behavioral and 
social deficits in children with the Val allele.  It is possible that, in the context of medical 
and behavioral difficulties, these academic and behavioral deficits do not predict 
caregiver report of children’s functioning within a 22q11DS sample.  This may be 
especially likely given that, as a group, children with 22q11DS exhibited deficits in most 
domains assessed relative to healthy children – to whom parents may be comparing their 
children when asked to report on global functioning.  Indeed, a previous report found that 
GAF scores differed between 22q11DS patients and control participants, with 22q11DS 
patients functioning significantly below the level of the control group (Lewandowski et 
al., 2007).  
Haplotype Analyses 
Seven of the 21 participants for whom genetic data was available were identified 
as haplotype-positive.  Patients who were haplotype-positive exhibited deficits in a 
number of cognitive domains including executive functioning, behavioral inhibition, 
working memory, processing speed, IQ, and math achievement compared to haplotype-
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negative participants.  Additionally, patients who were haplotype-positive exhibited 
poorer assertion and lower overall behavioral competency and social skills, and greater 
difficulties on social and behavioral measures.  These findings suggest that patients with 
22q11DS and a 2-or 3-marker COMT haplotype exhibit cognitive and behavioral deficits 
in general, and in specific areas that have been associated with premorbid functioning in 
patients who develop schizophrenia.   
Additionally, one participant had the 3-marker haplotype described by Shifman et 
al. (2002).  This patient’s cognitive and behavioral functioning was described, and 
compared to the 22q11DS group as a whole.  This participant exhibited deficits in all 
cognitive domains compared with normative data, and deficits in sustained attention and 
verbal learning and memory that were at least one standard deviation from the mean of 
the 22q11DS group as a whole.  These findings suggest that, compared with other 
children with 22q11DS, this patient was performing at the level that would be expected in 
terms of general intellectual ability and academic achievement, but exhibited specific 
difficulties in sustained attention and verbal learning.  Unfortunately, WCST data were 
not available for this patient.   
Additionally, this patient exhibited behavioral difficulties on the Withdrawn and 
Anxious/Depressed scales that were more than one standard deviation from the mean of 
the 22q11DS group and significantly higher than normative data.  Conversely, based on 
the questionnaire data, this patient exhibited significantly fewer behavior problems on the 
attention scale than the 22q11DS group as a whole, and scored in the average range on 
measures of externalizing difficulties based on normative data.  These findings suggest 
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that this patient exhibited specific difficulties in internalizing behaviors but not 
externalizing behaviors as compared to the general population and within a sample of 
patients with 22q11DS.  It is important to remember that these scores represent the 
unique functioning of a single participant who was positive for the 3-marker haplotype, 
and are thus descriptive only.  However, the findings suggest that the 3-marker haplotype 
may be associated with cognitive and behavioral difficulties that have been associated 
with premorbid functioning in schizophrenia, and may be involved in the 
neurodevelopment of psychosis.  Together, these findings represent the first investigation 
of putative schizophrenia susceptibility haplotypes in 22q11DS specifically, and in high-
risk samples generally.  Findings suggest that further investigation of these haplotypes is 
warranted.   
COMT and Markers of Schizophrenia  
The present findings indicate that the COMT Val158Met polymorphism is 
associated with cognitive and behavioral functioning that is related to premorbid 
adjustment in schizophrenia.  This suggests that COMT may play a role in 
neurodevelopment of vulnerability, although findings linking COMT with increased rates 
of schizophrenia have been inconclusive.  Rather, COMT may be more closely associated 
with specific neurocognitive and behavioral features than with diagnostic categories.  
While a number of behavioral and prefrontal cognitive measures were associated with 
genotype in the present study, broad measures of psychopathology were not.  
Additionally, within the 22q11DS group, the Val allele was associated with measures of 
behavioral, social, and cognitive dysfunction that have been detected in patients with 
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schizophrenia at premorbid, prodromal, active, and residual phases of illness.  This 
suggests that, while COMT does not demonstrate clear linkage to schizophrenia, 
genotype may be associated with pathophysiological processes that contribute to 
vulnerability to psychosis and are detectable in behavioral and cognitive manifestations 
of neuromaldevelopment.  Additionally, within 22q11DS, the present findings support 
the hypothesis that COMT genotype is associated with specific cognitive and behavioral 
impairment within a high-risk population.  Longitudinal studies will help clarify the 
relationship of these specific deficits to vulnerability to psychosis.   
COMT and Endophenotype Analysis   
Endophenotypes are hypothesized to offer more immediate links to candidate 
genes than fully expressed clinical disorders.  As such, this concept has utility in 
examining genetic inheritance, especially in complex diseases such as schizophrenia in 
which there may be multiple heritable dimensions (Cannon, 2005).  This indicates that 
specific features of schizophrenia may be more directly associated with distinct genetic 
and pathophysiological processes, and the identification of such endophenotypes may 
hasten the discovery of genes and pathways of influence in the neurodevelopment of 
psychosis.  Gottesman and Gould (2003) delineated several key criteria for 
endophenotypes, including an association with a specific gene or gene region, association 
with the disease, and heritability as detected in relatives.  The present findings support the 
examination of cognitive, and possibly behavioral and social, dysfunction as 
endophenotypes in schizophrenia, in keeping with the description by Gottesman and 
Gould.  Specific cognitive and behavioral deficits were detected in the present sample of 
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patients with 22q11DS, and were associated with the COMT Val158Met polymorphism.  
As described above, these cognitive and behavioral deficits have been associated with 
patients with schizophrenia at all phases of illness, and in other high-risk populations 
including first-degree relatives.  Additionally, the COMT Val158Met polymorphism may 
be more strongly associated with these cognitive and behavioral features than has 
schizophrenia itself.  Thus, the present findings support previous suggestions that 
cognitive (and possibly behavioral) deficits may represent endophenotypes in 
schizophrenia (Cannon, 2005).  Associations of COMT with putative endophenotypes in 
schizophrenia may yield tighter correlations than examination of COMT with diagnostic 
category, and may provide important information about disruptions in neurodevelopment 
and neurobiology that are associated with psychosis.  Better understanding of these 
relationships holds the promise of elucidating etiological and pathophysiological 
pathways in the development of the disease, and may hasten the development of 
treatments specifically targeted at these substrates.   
 It is likely that “intermediate phenotypes” including brain activity in regions of 
interest more sensitively measure gene effects (Smolka et al., 2005).  Indeed, 
examinations of brain functioning found that efficiency of processing in prefrontal cortex 
based on fMRI, and in the cingulate cortex on a task of attentional control, was 
significantly better in Met subjects (Egan et al., 2001; Heinz & Smolka, 2006).  Genotype 
was associated with activation of frontal and limbic regions during presentation of 
aversive emotional stimuli, but was unrelated to measures of anxiety or depression 
(Heinz & Smolka, 2006; Smolka et al., 2005).  Egan et al. (2001) found that Val allele 
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load predicted less efficient prefrontal response on the WCST in patients with 
schizophrenia, their unaffected siblings, and healthy controls.  Similarly, McIntosh et al. 
(2007) found that the Val allele was associated with increased activation in lateral 
prefrontal cortex and anterior and posterior cingulate as task demands increased despite a 
similar level of performance on the tasks.  Less direct measures of outcome may be 
affected by brain activity that reflects compensatory strategies and/or effects of genetic 
variation not associated with COMT, which may dilute findings.  The more directly 
specific aspects of brain functioning are measured, the stronger the association between 
genotype and outcome.  Functional imaging of prefrontal regions in association with the 
COMT genotype in patients with 22q11DS may continue to elucidate these relationships.  
Additionally, this suggests that the specificity of measures to hypothesized constructs of 
interest should be carefully considered in study design.   
Neurodevelopment, Cognitive Functioning, and COMT 
 Based on the hypothesis that schizophrenia is an extreme manifestation of a 
process of neuromaldevelopment, it is assumed that, for patients with the vulnerability, 
the brain is already developing along a disrupted trajectory, which likely involves the 
prefrontal cortex (PFC).  Indeed, we see poor prefrontal functioning in our 22q11DS 
patients as a whole relative to normal controls and over and above the level that would be 
expected based on intellectual abilities (Lewandowski et al., 2007).  Additionally, 
patients with the Val allele perform especially poorly on several measures of working 
memory, reasoning, and attention. 
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 Based on a developmental model, we would expect to see attenuated deficits on 
specific tasks until the brain region presumed to mediate performance on such tasks is 
fully-developed.  Thus, the timing of development in PFC is an important variable in the 
investigation of schizophrenic-like deficits in patients with 22q11DS.  This is because 
typically-developing children would be expected to improve substantially on tasks that 
recruit the PFC as this region matures; however, it is hypothesized that children with 
disruptions in PFC will exhibit increasing deficits relative to their peers as 
neurodevelopmental processes act on already disrupted pathways.   
In primates, functional maturation of the PFC is protracted, with adult levels of 
functioning not being reached until puberty (Chugani & Chugani, 1997).  Frontal lobe 
activity is enhanced on tasks requiring higher-level processing during adolescence and 
young adulthood, despite a reduction in total volume and metabolism in PFC during 
adolescence (Casey, Geidd, & Thomas, 2000; Rubia et al., 2000).  Gray matter volume 
reductions in cortical areas reflect planned pruning and refinement of connections, and 
are related to enhanced performance on tasks that are mediated by this region (Giedd et 
al., 1999; Jernigan, Trauner, Hesselink, & Tallal, 1991; Sowell & Jernigan, 1998; Sowell, 
Thompson, Tessner, & Toga, 2001).  This suggests that volumetric decreases in cortical 
areas during adolescence reflect refinement rather than degeneration.   
Neurodevelopment in adolescence.  In adolescence, the peak of brain activity 
occurs in PFC.  Evidence from tasks believed to tap functioning in this region indicates 
that many of these are too difficult for young children but become much more 
manageable for adolescents as brain development in the PFC reaches maturity.  
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Maturational processes allow for refinements of existing abilities including speed and 
capacity of information processing (Luna & Sweeny, 2004).  A study of healthy 9-18 
year-olds found significant age-effects in abstract reasoning, response inhibition, and 
attentional set shifting, with these skills becoming available during peripuberty and 
continuing to improve throughout adolescence (Rosso, Young, Femia, & Yurgelun-Todd, 
2004).  Thus, functioning that is dependent on PFC should be severely impaired by 
anomalies involving in development during and after adolescence, but should be less 
affected in early years when brain metabolic activity is lower in frontal areas (Vicente & 
Kennedy, 1997) 
Indeed, while cognitive and behavioral deficits are often present throughout 
childhood in people who will go on to develop schizophrenia, cognitive deficits and 
academic and behavioral problems increase in adolescence (Fuller et al., 2002), 
supporting a role of PFC dysmaturation in schizophrenia.  It is presumed that typical 
neurodevelopmental processes further compromise structure and function of PFC leading 
to increased deficits in functioning with regard to tasks mediated by this region.  
Furthermore, increased relative impairments in preschizophrenic adolescents may be 
reflective of increasing task demands surrounding social and cognitive performance 
mediated by PFC.  Thus, these demands are easier to meet for typically-developing 
adolescents than for preschizophrenic adolescents, whose PFC structure and connectivity 
are compromised.   
There is evidence of over-pruning in dorsolateral PFC in schizophrenic patients, 
in which normal pruning processes are exceeded (Giedd et al., 1999; Selemon, 
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Rajkowska, & Goldman-Rakic, 1995).  This may result from an excess of unused 
connections due to errors in neuronal migration and organization, or reduction of 
opportunities for long-term potentiation, suggesting that neural abnormalities in PFC that 
occurred during brain development and organization and were resultantly unusable 
during childhood become subject to over-pruning in adolescence.  Additionally, imaging 
studies have suggested that the PFC may be reduced in size and functioning in 
schizophrenic patients compared to controls (Berman, Torrey, Daniel, & Weinberger, 
1992; Black et al., 2004; Glantz & Lewis, 2000; Gur et al., 2000; Selemon, Rajkowska, & 
Goldman-Rakic, 1995).  A large body of evidence suggests that people with 
schizophrenia experience diminished PFC functioning, or hypofrontality, during working 
memory tasks, as well as logical reasoning and other tasks that are mediated by this 
region (Barch et al., 2001; Callicott et al., 2000; Carter et al., 1998; Fletcher et al, 1998; 
Ramsey et al., 2002; Stevens et al., 1998).  Weinberger, Berman, and Illowski (1988) 
found that patients with schizophrenia showed reductions in regional cerebral blood flow 
(rCBF) in dorsolateral PFC during the WCST, but not during number-matching task, 
which is a non-prefrontal measure.  Additionally, patients with schizophrenia did not 
activate dorsolateral PFC above their baseline (based on the number-matching task) 
during the WCST performance.  
 The average age at assessment of the present sample was approximately 9 years. 
Thus, we would expect that performance on tasks that require PFC activation in this 
group of patients with 22q11DS to worsen compared to their healthy peers as the 
prefrontal cortex reaches maturity.  Since this does not happen until adolescence or early 
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adulthood, we would expect that relative deficits in functioning will continue to increase 
as our sample reaches young adulthood. 
Additionally, it is possible that the mechanisms within the prefrontal cortex that 
affect functioning in this region may play a more apparent role as development 
progresses.  In the present sample, the COMT Val158Met polymorphism, which has a 
substantial effect on prefrontal dopamine levels, may become more strongly associated 
with performance on tasks that assess functioning mediated by this region.  Conversely, 
the relationship between the Val158Met polymorphism and prefrontally-mediated 
functioning may change in more complex ways.  For instance, cognitive tasks assessed in 
the present study are presumed to be affected by prefrontal dopamine functioning.  The 
present findings suggest that, consistent with findings from other samples with 22q11DS 
as well as nondeleted participants, patients with the Val allele perform worse on such 
tasks due, at least in part, to reductions in dopamine availability.  However, as 
Weinberger noted, there is likely an “optimal” window of dopamine availability in PFC, 
such that reductions in dopamine (as seen in Val/Val individuals) and excesses in 
dopamine may result in similar detriment to performance on tasks that rely on this 
process.  As a result, development may interact with dopamine functioning in 22q11DS 
such that dopamine changes in adolescence move patients with the Met allele out of the 
optimal window of dopamine availability, resulting in poorer cognitive functioning in 
young adulthood.  Again, longitudinal investigation of the present sample will help 
elucidate some of these questions.   
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 In sum, deficits in prefrontally-mediated functioning are evident in patients with 
22q11DS in childhood – well before maturation in this region is completed and well 
before expected onset of symptoms.  This is consistent with a neurodevelopmental model 
of schizophrenia, and suggests that cognitive and behavioral impairments will worsen as 
our sample reaches adolescence and early adulthood.  COMT may play a role in 
disrupted functioning in this region, as it affects dopamine regulation in the synapse.  
Additionally, COMT may play a role in neurodevelopment and pathophysiology of 
schizophrenia, affecting dopaminergic functioning in prefrontal regions in particular, 
which have been hypothesized to play a central role in the etiology and pathogenesis of 
psychosis.  In addition to dysfunction on prefrontally-mediated cognitive tasks, it would 
be expected that COMT would be associated with other social and behavioral deficits that 
are likely affected by prefrontal functioning.  Indeed, the present findings suggest that 
social and behavioral impairments are associated with COMT genotype.  
Developmentally, this may set the stage for continued disruption in development through 
childhood and into adolescence and early adulthood, as discussed above. 
Gene-By-Gene Interactions and Haplotype Analysis 
 
It is likely that complex interactions affect the relationship of COMT on 
phenotypic outcome measures in schizotypy, including diagnosis.  The Val158Met 
polymorphism may interact with other loci in the COMT gene and with other genes.  
Indeed, preliminary examination of COMT haplotypes described by Shifman et al. (2002) 
and Funke et al. (2005) in the present sample of patients with 22q11DS suggest that these 
haplotypes are more common in patients with 22q11DS than in a previously identified 
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control group, and are associated with schizophrenic-like cognitive and behavioral 
deficits.  Additionally, the Val158Met allele may interact with genes in other regions, 
creating complex gene-by-gene interaction effects.  For instance, Nicodemus et al. (2007) 
reported a significant increase in risk for schizophrenia associated with three RGS4 SNPs 
in interaction with COMT, while the main effects for RGS4 SNPs were null.  In healthy 
subjects, Smolka et al. (2007) observed an additive effect of the COMT Met and 5-HTT 
low expressing alleles on regional blood oxygen level-dependent response to aversive 
stimuli, with the interaction accounting for 40% of the inter-individual variance.  
Haplotype and gene-by-gene analyses such as these may improve prediction not only in 
terms of schizophrenia, but in terms of cognitive and behavioral features associated with 
psychosis.  These findings, together with preliminary data from the present investigation, 
support the extension of haplotype analyses to more homogeneous features associated 
with schizophrenia, including putative endophentypes.  While these studies require large 
samples, as the likelihood of achieving a group of sufficient size to detect differences 
decreases exponentially with each marker that is added to the haplotype, they may yield 
more robust associations between genotype and phenotype.   
 Finally, it is important to remember that the Val158Met polymorphism is in Hardy-
Weinberg equilibrium, meaning that it is distributed throughout the population.  This 
suggests that, while COMT may play a role in etiology and pathogenesis of psychosis, it 
is unlikely that this gene is causally related to schizophrenia in a monogenic fashion.  It is 
more likely that COMT is associated with an endophenotype of schizophrenia, and plays 
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a role in the complex neurodevelopment of psychosis, along with many other genes and 
interactions.  
COMT Interactions by Sex, Environment, and Maturation 
 In addition to gene-by-gene interactions, other factors likely interact with COMT 
to affect phenotypic expression.  Such factors may include environmental effects on brain 
and gene expression and the effects of maturational processes and sex on outcome 
measures.  For instance, the COMT Met allele was associated with anxiety in women but 
not in men (Enoch et al., 2003), and a recent report found that COMT genotype predicted 
general intelligence in boys but not girls, and that these effects increased with maturation 
(Barnett et al., 2007).  In fact, one would expect these differences to become much more 
pronounced with the onset of puberty. This suggests that sex and maturational factors can 
moderate the effects of COMT genotype on phenotype.  While our sample size was not 
sufficient to examine effects by sex, the groups did not differ on the proportion of males 
and females.  As the sample increases, these analyses will be important to consider.  
Additionally, as our sample continues to age, the effects of maturational variables in 
combination with gender will be increasingly important. 
 Exposure to environmental factors that play a role in schizophrenia pathogenesis 
may also interact with genotype in complex ways.  Caspi et al. (2005) reported that 
psychotic symptoms and diagnosis of schizophreniform disorder were not associated with 
COMT genotype.  However, they found a significant interaction between genotype and 
adolescent cannabis use in people who reported psychotic symptoms or met criteria for 
schizophreniform disorder.  Interestingly, there was no interaction effect of adult onset 
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cannabis use and genotype on diagnosis of schizophreniform disorder or reported 
psychotic symptoms, suggesting that this interaction may be sensitive to maturational 
variables.  These findings indicate that gene associations may remain undetectable absent 
environmental risk, reducing the likelihood of detection of reliable associations (Caspi et 
al., 2005).  Similar gene-by-environment findings – absent main effects of the genetic 
marker – have been detected in other studies of complex human disease (Caspi et al., 
2002; Caspi, Sugden, Moffitt, Taylor, & Craig, 2003; Kendler, Kuhn, Vittum, Prescott, & 
Riley, 2005).  Such complex analyses require large samples and longitudinal follow-up, 
and will be important to consider as we follow our participants over time.   
 Additionally, effects of maturation and timing of exposure may be of importance, 
and maturational factors may be important in terms of measurement, as well.  For 
instance, given the apparent role of COMT in prefrontal functioning and the protracted 
nature of maturation in this brain region, with adult-level structural, functional, and 
cognitive outcomes not reached until late adolescence or early adulthood, effects of 
compromised neurotransmitter regulation in this region may not be apparent until adult 
levels of prefrontally-mediated functioning are achieved, as discussed above.  Similarly, 
exposure to risk factors believed to affect prefrontal pathways may have no detectable 
effect on phenotype if the exposure occurs outside of a developmentally-sensitive period.  
This underscores the importance of theoretically-driven hypothesis testing, as such 
models can attempt to account for maturational factors a priori.  Within our present 
sample, a number of factors should be examined in terms of insults to maturation and 
neurodevelopment as our sample size permits.  For instance, there is considerable 
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heterogeneity in our sample in terms of medical complications and interventions, 
including perinatal complications, exposure to general anesthesia, time spent in the 
hospital, immunological deficiencies, and cardiac and palate abnormalities.  Additionally, 
factors like parental psychopathology, especially schizotypy and schizophrenia, should be 
considered, as there may biological and environmental effects on children based on 
having a parent with psychosis.  These factors and their timing may affect neural 
development, and should be accounted for as our sample increases in size enough to 
group patients based on these factors, and through longitudinal follow-up to examine the 
effects on functioning through development.   
While evidence for a causal role in schizophrenia remains inconclusive, COMT 
continues to represent a promising candidate for examination of genetic effects on the 
pathogenesis of schizophrenia and related disorders.  However, associations between 
genotype and specific symptoms and markers – rather than the “syndrome” of 
schizophrenia itself – may hold more promise.  In fact, issues with associations between 
biological markers and heterogeneous disorders such as schizophrenia have been noted 
for decades.  Luchins (1975) suggested, “…that research directed towards studying 
dopaminergic mechanisms in specific psychopathological symptoms, not syndromes, 
might prove fruitful.”  Thus, associations between COMT and endophenotypes should be 
pursued.  Such investigations provide logical starting points, as complex disorders are 
characterized by a variety of disparate symptoms, and classification strategies often 
produce groups that are not homogeneous.  Additionally, it is simultaneously unlikely 
that a single gene or SNP will account for substantial variance in complex human disease 
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and likely that a single gene or SNP will be associated with multiple outcomes.  This may 
account for both failures to replicate associations, and non-specific associations between 
a genetic locus and multiple variables.  Investigations of gene associations should be 
driven theoretically by hypothesized or known effects on functioning, and these outcome 
measures may be linked to the neurodevelopment of vulnerability to schizophrenia, 
movement along the continuum, decompensation, or protective factors.   
Other factors may reduce the strength of the association between COMT 
functioning and schizophrenia, including compensatory brain functioning and other 
protective factors, and the heterogeneity of schizophrenia itself as it is currently 
formulated.  For example, schizophrenia and schizotypy have been hypothesized to be 
multidimensional constructs, with candidate factors including positive, negative, and 
cognitive disorganization (e.g. Claridge et al., 1996; Lewandowski et al., 2006; Mason, 
Claridge, & Williams, 1997; Vollema and van den Bosch, 1995).  Disease course, 
associated traits, and treatment efficacy associated with these factors may actually be 
distinct.  Positive schizotypy has been associated with higher rates of depression and 
anxiety symptoms (Lewandowski et al., 2006), and negative schizotypy has been 
associated with social disinterest (Brown et al., in press).  Negative (but not positive) 
symptoms are correlated with greater impairment in cognition and social functioning 
(McGurk et al., 2000), and negative symptoms are more persistent, while positive 
symptoms tend to decrease with age (Fenton & McGlashon, 1991).  Cognitive 
impairment is associated with poor community functioning (Green, Kern, & Heaton, 
2004), and may be a stronger correlate of poor outcome than any other symptom domain 
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(Green, 1996).  Additionally, pharmacological therapies tend to address positive 
symptoms more effectively than negative symptoms and cognitive disorganization, 
although atypical antipsychotics appear to confer some improvement in these domains 
compared with their older-generation counterparts (Burton, 2006).  Examination of 
biological variables in association with schizotypy factors may help increase the 
likelihood of finding meaningful associations between grouping variables and genetic or 
neurobiological factors that may be washed out in more heterogeneous groups 
(Lewandowski, in press).  Thus, caution must be exercised when describing associations 
between COMT and schizophrenia, and strategies that attempt to link COMT (or any 
other genetic) variation to specific symptoms may prove more fruitful. 
Future Directions 
 The present study is a cross-sectional examination of the association of COMT 
genotype and cognitive and behavioral risk markers of psychosis in a putatively 
schizotypic sample.  These findings represent preliminary data regarding these 
associations, as well as preliminary descriptions of a COMT haplotype in 22q11DS.  
Interpretations of the present findings were limited by sample size, which underpowered 
the study.  Additionally, the small sample size prevented the investigation of the possible 
effects of variables such as age and gender on outcome measures.  As the sample size 
increases, such investigations will be permitted, which may demonstrate the presence of 
complex interactions amongst variables.  Additionally, the present sample is being 
followed prospectively.  As follow-up data become available, the relationships of genetic, 
cognitive, and behavioral variables with the development of psychopathology, and 
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schizophrenia-spectrum disorders specifically, can be examined.  Prospective 
investigation will inform the utility of cognitive and behavioral deficits as 
endophenotypes, as has been hypothesized.  Specifically, cognitive processes that involve 
frontal lobe-mediated working memory and executive functioning may represent a 
distinct heritable dimension in schizophrenia (Cannon, 2005).  
Children with 22q11DS exhibit an array of cognitive, behavioral, and psychiatric 
difficulties that may have implications for later psychiatric outcome and adjustment. 
Identification of features that precede the onset of clinical symptoms is important in 
understanding the neurodevelopmental processes that contribute to later adjustment, as 
well as the development of early intervention strategies (Murphy, 2005). Substantial 
heterogeneity of symptoms exists among individuals with this syndrome.  Continued 
examination of cognitive and behavioral deficits within this group may help confirm 
specific risk markers for the development of psychosis. Continued investigation of this 
population, including studies of premorbid and prodromal symptoms and areas of 
dysfunction, may help refine our understanding of which children will go on to develop 
schizophrenia.  Additionally, such work may improve our understanding of the 
etiological pathway(s) of schizophrenia and clarify factors that further contribute to risk. 
Such an understanding may increase accuracy in identification of persons at risk, 
improving the effectiveness of prophylactic treatment efforts. 
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APPENDIX A. TABLES 
Table 1 
Group Demographic Characteristics 
 
Met     Val 
 
   (n = 13)      (n = 14) 
      
Age     9.1 (2.0)   9.7 (3.1) 
Gender  38% female   36% female 
Ethnicity  100% Caucasian/  86% Caucasian/ 
   0% African American     14% African American 
Social Position 37.7 (12.5)     36.1 (15.8) 
Education (years)   1.9 (1.7)        2.6 (3.0) 
Global Adjustment 63.9 (9.5)   59.1 (10.0) 
 
Note: all comparisons were non-significant 
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Table 2 
Means and Standard Deviations of Neurocognitive Measures by Group  
 
        Met (n=13)    Val (n=14)   t-test         Cohen’s d 
              
Continuous Performance Test 
 
CPT-IP        .14 (.26)    .31 (.33)   -1.52  -.57 
  
  AX    1.42 (.77)    .88 (1.02)    1.55†    .60 
 
Wisconsin Card Sorting Test 
 
Perseverative    86.2 (10.0)   89 .8 (11.6)      -.85  -.33 
  
Non-Perseverative 86.5 (11.3)   80.8 (21.2)       .86†   .34 
    
 % Conceptual Level 85.1 (8.2)   80.8 (15.6)        .88   .35 
 
   
California Verbal Learning Test-Children’s Version 
 
List A1-5z  -1.07 (.74)      -1.09 (1.18)        .04    .02 
  
List A1     -.77 (1.38)    - .71 (1.44)       -.10   -.04 
  
Short Delay Free  -.77 (.73)   -1.00 (1.41)        .53    .20 
   
Short Delay Cued  -.96 (.75)    -1.39 (1.39)        .99    .39 
   
Long Delay Free -1.12 (1.12)    -1.25 (1.53)        .26    .10 
   
Long Delay Cued  -.85 (1.13)   -1.25 (1.41)         .82    .31 
   
Serial Clustering  -.54 (.80)    -.50 (1.00)       -.11   -.04 
   
Semantic Clustering   .00 (.91)     -.04 (1.29)        .08    .04 
   
        
 
† : Equality of Variances not met (Levene’s Test, p < .05), so t statistics reported and 
corresponding p values are based on unequal variances.  
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Table 3 
WISC-III Means and Standard Deviations by Group 
 
              Met (n = 13)     Val (n = 14) t-test     Cohen’s d 
          
Scale Scores 
Full Scale IQ   76.1 (10.7) 66.1 (12.4) 2.19**  .86 
 
Verbal IQ   79.6 (10.0) 70.0 (12.1) 2.18**  .86 
 
Performance IQ  76.5 (11.4) 70.2 (14.2) 1.25   .49 
 
Factor Scores 
Verbal Comprehension 80.6 (10.1) 72.0 (13.0) 1.83*  .74 
 
Perceptual Organization 76.7 (11.8) 68.5 (14.4) 1.60  .62 
 
Working Memory  83.3 (12.0) 70.1 (14.2) 2.40**  1.00  
 
Processing Speed  86.0 (16.0) 73.3 (13.8) 2.09**  .85 
 
Subtest Scores 
Block Design    6.0 (3.1)  4.7 (2.7) 1.16  .45  
 
Similarities    6.9 (2.6)  5.4 (2.9) 1.35  .54 
 
Digit Span    7.2 (2.4)  5.8 (2.7) 1.27  .55 
 
Coding    6.9 (2.7)  5.8 (3.1) 1.02  .38 
 
Vocabulary    6.1 (2.3)  4.8 (2.5) 1.34  .54  
 
Comprehension   5.8 (2.9)  4.5 (3.3) 1.02  .42  
 
Symbol Search   7.5 (3.8)  4.3 (2.7) 2.36**  .97 
 
Information    6.7 (2.6)  5.0 (1.7) 1.68  .77 
 
Arithmetic    6.0 (2.4)  3.4 (3.5) 1.98*  .87 
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Picture Completion   5.9 (2.9)  3.8 (1.7) 1.94*  .88 
 
Picture Arrangement   6.1 (2.4)  2.8 (1.6) 3.56*** 1.62 
 
Object Assembly  5.3 (2.7)  4.8 (3.6)  0.40  .16 
 
 
*** = p<.01   ** = p<.05      * = p<.10 
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Table 4 
WIAT-II Means and Standard Deviations by Group 
 
     Met (n = 13)  Val (n = 14)   t-test     Cohen’s d 
       
Broad Reading  87.8 (16.4) 76.4 (19.1)   1.62        .64 
 
Word Reading   88.8 (9.9) 77.9 (20.0)   1.68        .69 
 
Reading Comprehension 84.6 (17.0) 73.8 (19.5)   1.47        .59 
 
Pseudoword Decoding 94.1 (17.0) 85.7 (17.5)   1.06        .49 
 
Broad Mathematics   77.3 (14.2) 65.5 (16.9)   1.96*        .76 
 
Math Reasoning  82.2 (15.3) 66.4 (14.3)   2.78**      1.07 
 
Numerical Operations  78.1 (12.6) 69.6 (19.8)   1.31        .51 
  
Spelling    85.9 (13.3) 76.8 (19.3)   1.42        .55 
 
 
*** = p<.01     ** = p<.05 * = p<.10 
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Table 5 
CBCL Means and Standard Deviations by Group 
             Met (n = 13)          Val (n = 14)            t-test       Cohen’s d  
Competency Total  36.0 (9.0)       32.5 (4.1)  1.07  .50  
Problem Scales†  
 Withdrawn  58.5 (6.3)       62.9 (8.6)  -1.3  -.58 
 Somatic  64.4 (8.8)       63.5 (11.3) .20  .09 
 Anxious/Depressed 55.9 (6.8)       63.1 (8.2)  -2.14** -.96 
 Social   62.3 (12.3)       64.1 (7.7)  -.39  -.18 
 Thought Problems 59.7 (10.9)       58.6 (10.0) .24  -.18 
 Attention  64.8 (9.2)       62.7 (10.5) .48  .21 
 Delinquent  55.2 (5.6)        54.8 (6.1)  .15  .07 
 Aggressive  52.9 (3.7)       57.5 (6.1)  -2.03*  -.91 
 Internalizing  54.2 (17.8)       62.8 (14.7) -1.12  -.53 
 Externalizing  50.0 (8.2)       54.9 (9.4)  -1.24  -.56 
 Total Problem  59.2 (10.2)       62.4 (11.4) -.66  -.30 
 
† Note: Higher scores on problem scales indicate poorer functioning.    
** = p<.05 * = p<.10 
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Table 6 
SSRS Means and Standard Deviations by Group 
             Met (n = 13)          Val (n = 14)            t-test       Cohen’s d  
Social Skills Scale 
 Cooperation  10.8 (2.7)       9.7 (4.1)  .75  .32 
 Assertion  16.7 (2.8)       11.9 (3.9)  3.23*** 1.41 
 Responsibility  13.6 (3.5)       11.0 (5.0)  1.38  .60 
 Self-Control  11.6 (2.3)       11.2 (4.6)  .27  .11 
 Skills Total  98.8 (13.9)       84.9 (21.7) 1.74*  .76 
 (Standardized)  
 
Problem Scales† 
 Externalizing  3.5 (1.7)       4.5 (2.7)  -1.01  -.44 
 Internalizing  4.8 (2.0)       5.6 (3.0)  -.71  -.31 
 Hyperactivity  5.2 (3.0)       6.4 (4.7)  -.64  -.30 
 Problem Total  104.1 (14.0)       108.3 (16.4) -.64  -.28 
 (Standardized) 
 
† Note: Higher scores on problem scales indicate poorer functioning.    
*** = p<.01 * = p<.10 
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Table 7 
Childhood Psychopathology and Global Functioning by Group 
     Met (n = 13)  Val (n = 14)  Fisher’s Exact 
            Test 
 
Social Phobia    0   2   .48 
Separation Anxiety   2   1   .60 
Specific Phobia   5   4   .70 
Panic Disorder   1   0   .48 
Agoraphobia    1   0   .48 
Generalized Anxiety   2   0   .22 
OCD     2   2   1.00 
PTSD     0   1   1.00 
Any Anxiety Dx   5   8   .45 
Major Depression   1   0   .48 
Depression NOS   0   1   1.00 
Any Depressive Dx   1   1   1.00 
AD/HD    7   4   .25 
Oppositional-Defiant   2   4   .65 
Any Diagnosis   7   10   .44 
        Met (n = 13)     Val (n = 14)   t-test 
 
Hyperactive (symptoms)  2.9   2.2   .54 
 
Inattention (symptoms)  5.5   3.8   .16 
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Note: The categories Dysthymia, Bipolar I, Bipolar II, Schizophrenia, Schizoaffective, 
Psychosis NOS, and Conduct Disorder were not computed because there were no 
participants who met criteria for these diagnoses. 
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Table 8 
 
Means and Standard Deviations of Neurocognitive Measures by Haplotype  
 
           Positive (n = 7)    Negative (n = 21)   t-test      Cohen’s d 
          
              
Continuous Performance Test 
 
CPT-IP        .33 (.44)    .14 (.24)    1.27   .54 
  
  AX      .66 (1.06) 1.12 (.91)   -1.03   -.47 
 
Wisconsin Card Sorting Test 
 
Perseverative    88.8 (10.4)   87 .6 (11.6)       .20   .11 
  
Non-Perseverative 67.6 (11.2)   91.2 (15.1)    -3.18*** -1.78 
    
 % Conceptual Level 71.8 (5.5)   88.1 (11.7)    -2.95***  -1.78 
 
   
California Verbal Learning Test-Children’s Version 
 
List A1-5z  -1.46 (1.07)     -.98 (1.45)     -1.27   -.38 
   
List A1    -1.14 (1.28)    - .93 (1.45)       -.33   -.15 
  
Short Delay Free -1.57 (1.62)     -.75 (.80)     -1.58   -.64 
   
Short Delay Cued -1.50 (1.76)    -1.11 (.84)       -.70    -.28 
   
Long Delay Free -1.43 (1.67)    -1.21 (1.17)       -.34   -.15 
   
Long Delay Cued -1.64 (1.70)     -.86 (1.12)      -1.28   -.54 
   
Serial Clustering   -.43 (1.13)     -.61 (.86)        .40    .18 
   
Semantic Clustering    .07 (.98)      .04 (1.34)        .06    .03 
   
        
*** = p<.01   
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Table 9 
WISC-III and WIAT-II Means and Standard Deviations by Haplotype 
 
        Positive (n = 7)   Negative (n = 21)  t-test     Cohen’s d 
          
WISC Scale Scores 
Full Scale IQ   61.7 (10.4) 72.9 (12.4)   -2.03* -.98 
 
Verbal IQ   66.7 (10.3) 77.1 (12.3)   -1.89* -.92 
 
Performance IQ  64.6 (11.4) 73.7 (12.8)   -1.60   -.75 
 
WISC Factor Scores 
Verbal Comprehension 68.7 (11.5) 78.5 (12.8)   -1.60  -.81 
 
Perceptual Organization 61.5 (8.3) 72.9 (13.5)   -1.90* -1.02 
 
Working Memory  65.0 (9.7) 79.9 (13.0)   -2.45** -1.30  
 
Processing Speed  67.7 (11.3) 85.5 (16.9)   -2.32** -1.24 
 
WISC Subtest Scores 
Block Design    4.3 (2.6)  5.4 (3.2)     -.78  -.38  
 
Similarities    5.1 (3.2)  6.8 (3.1)   -1.09  -.54 
 
Digit Span    4.8 (2.0)  7.1 (2.3)   -2.01* -1.07 
 
Coding    4.6 (2.7)  7.2 (2.9)   -2.00* -.93 
 
Vocabulary    3.6 (1.9)  6.1 (2.5)   -2.28** -1.16  
 
Comprehension   3.7 (2.5)  5.2 (3.4)   -1.04  -.50  
 
Symbol Search   3.0 (1.9)  7.1 (3.7)   -2.53** -1.39 
 
Information    5.0 (2.1)  6.2 (2.5)   -1.04  -.52 
 
Arithmetic    3.0 (1.9)  5.8 (2.9)   -1.90* -1.14 
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Picture Completion   3.5 (1.6)  5.6 (2.9)   -1.62* -.90 
 
Picture Arrangement   3.0 (1.9)  5.3 (2.8)   -1.84* -.96 
 
Object Assembly   5.2 (3.5)  4.9 (3.1)      0.15   .09 
 
WIAT-II Broad Reading  77.9 (22.6) 86.6 (16.2)   -1.01  -.44 
 Word Reading   78.7 (23.2) 88.6 (9.9)   -1.31  -.56 
 Reading Comprehension 75.1 (21.7) 83.6 (17.7)   -0.92  -.43 
 Pseudoword Decoding 84.3 (27.5) 94.9 (16.6)   -0.84  -.47 
WIAT-II Broad Math   62.9 (14.0) 74.6 (14.6)   -1.77* -.82 
 Numerical Operations  63.3 (16.2) 77.1 (12.4)   -2.17** -.96 
 Math Reasoning  66.0 (14.2) 78.6 (16.2)   -1.74* -.83 
WIAT-II Spelling   78.8 (21.4)  84.7 (13.5)   -0.77  -.33 
 
*** = p<.01   ** = p<.05      * = p<.10 
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Table 10 
 
CBCL Means and Standard Deviations by Haplotype 
           Positive (n = 6)    Negative (n = 21)  t-test       Cohen’s d  
Competency Total  33.8 (3.5)       42.0 (11.6) -2.79** -.96  
Problem Scales†  
 Withdrawn  62.0 (9.7)       57.0 (7.4)   1.36   .58 
 Somatic  62.8 (14.0)       59.2 (9.6)     .74   .30 
 Anxious/Depressed 61.3 (9.8)       55.5 (7.1)   1.64   .68 
 Social   60.3 (6.9)       59.1 (11.0)    .25   .13 
 Thought Problems 58.2 (10.4)       55.3 (8.7)     .68   .30 
 Attention  58.0 (5.4)       61.4 (11.2)   -.71  -.39 
 Delinquent  53.0 (5.9)       54.1 (4.4)   -.48  -.21 
 Aggressive  55.8 (6.1)       54.0 (5.2)      .73    .32 
 Internalizing  59.2 (18.2)       52.5 (15.1)    .91    .40 
 Externalizing  51.8 (10.3)       49.9 (9.2)     .44    .19 
 Total Problem  58.8 (12.6)       54.6 (12.7)  -.66    .33 
 
† Note: Higher scores on problem scales indicate poorer functioning.    
** = p<.05   
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Table 11 
SSRS Means and Standard Deviations by Haplotype 
           Positive (n = 7)     Negative (n = 21) t-test       Cohen’s d  
Social Skills Scale 
 Cooperation  10.0 (4.7)       11.1 (2.7)  -.76   -.29 
 Assertion  11.4 (3.8)       16.1 (3.6)           -2.97***           -1.27 
 Responsibility  11.7 (6.3)       13.4 (3.8)  -.85   -.33 
 Self-Control  11.3 (5.1)       12.1 (4.0)  -.46   -.17 
 Skills Total  86.1 (23.1)       98.6 (19.9)          -1.38   -.58 
 (Standardized)  
 
Problem Scales† 
 Externalizing  3.3 (1.8)       4.1 (2.7)  -.78   -.35 
 Internalizing  5.0 (2.9)       4.4 (2.5)   .50     .22 
 Hyperactivity  5.6 (6.1)       5.2 (2.8)   .21     .08 
 Problem Total  102.3 (12.4)       104.2 (17.3) -.28   -.13 
 (Standardized) 
 
† Note: Higher scores on problem scales indicate poorer functioning.    
*** = p<.01 ** = p<.05 * = p<.10 
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Table 12 
Cognitive Functioning in Patient with 3-Marker Haplotype 
                Patient with 3-marker  22q11DS 
            Haplotype      Group 
             
WISC-III  
 FSIQ      71      71.4 (11.9) 
 VIQ      73      73.9 (12.1) 
 PIQ      73      74.3 (13.2) 
WIAT-II 
 Broad Reading     80      82.7 (17.3) 
 Reading Comprehension    63      80.6 (18.4) 
 Broad Mathematics    64      72.0 (16.0) 
 Numerical Operations    62      74.6 (17.1) 
 Math Reasoning     66      74.9 (15.6)  
 Spelling      75      82.3 (16.1) 
CPT 
 IP       -.17     .20 (.29)* 
 AX      .44     1.04 (1.03) 
CVLT-C 
 List A1-5z      -2.7      -1.0 (0.9)* 
 List A1      -2.0      -0.7 (1.3)* 
 Short Delay Free     -2.5      -0.8 (1.1)* 
 Short Delay Cued     -2.5      -1.0 (1.1)* 
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 Long Delay Free     -2.0      -1.0 (1.3) 
 Long Delay Cued     -2.5      -0.9 (1.2)* 
 Serial Clustering     -1.5      -0.4 (0.9)* 
 Semantic Clustering    0.5       0.0 (1.1) 
* = ≥ 1 standard deviation below the 22q11DS mean 
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Table 13 
Behavioral and Social Measures in Patient with 3-Marker Haplotype 
               Patient with 3-Marker       22q11DS Group 
             Haplotype 
 
CBCL Competency Total    34   34.9 (7.6) 
CBCL Problem Scales†  
 Withdrawn     73   61.2 (8.3)* 
 Somatic    67   62.2 (9.9) 
 Anxious/Depressed    69   59.4 (8.4)* 
 Social      65   61.8 (9.5) 
 Thought Problems    64   58.0 (9.6) 
 Attention     52   63.0 (9.9)^ 
 Delinquent     50   54.4 (5.3) 
 Aggressive     52   54.7 (5.3) 
 Internalizing     72   58.1 (16.1) 
 Externalizing     48   51.6 (9.0) 
 Total Problem     63   59.7 (10.8) 
SSRS Social Skills Scale 
 Cooperation     7   10.3 (3.8) 
 Assertion     11   15.1 (6.7) 
 Responsibility     12   15.6 (18.8) 
 Self-Control     10   11.1 (4.1) 
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 Skills Total     81   88.0 (25.6) 
 (Standardized)  
SSRS Problem Scales† 
 Externalizing    4   4.2 (2.2) 
 Internalizing    6   5.3 (2.7) 
 Hyperactivity    1   9.1 (17.2) 
 Problem Total     94   106.0 (15.1) 
 (Standardized) 
 
† Note: Higher scores on problem scales indicate poorer functioning 
* = ≥ 1 standard deviation from the 22q11DS mean 
^ = ≤ 1 standard deviation from the 22q11DS mean 
 
 
 
